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 Human retinitis pigmentosa (RP) typically involves decades of progressive vision 
loss before some patients become blind, and prospective therapies target patients who have 
been blind for substantial time, even decades. Evaluations of molecular and cellular 
therapies have primarily employed short-lived mouse models lacking the scope of 
remodeling common in human RP. The Rho Tg P347L transgenic rabbit offers a unique 
opportunity to evaluate the primary degeneration event and subsequent progressive 
remodeling that ensues over a timespan that recapitulates the human disease phenotype. 
Retinas from a TgP347L rabbit model of human dominant RP and wild-type litter mates 
were harvested over an 8-year span and processed for transmission electron microscope 
connectomics, immunocytochemistry for a range of macromolecules, and computational 
molecular phenotyping for small molecules, including transport tracing with D-Asp. Early 
time points in the TgP347L rabbit recapitulate the established sequence of photoreceptor 
loss, retinal remodeling, and reprogramming, and also reveal progressive disruptions in 
Müller cell metabolism, where rather than observing a homogeneous glial population, 
chaotic metabolic signatures emerge. By 4 years, virtually all remnants of photoreceptors 
are gone and the neural retina manifests severe cell loss and near complete loss of 
glutamine synthetase, though glial glutamate transport persists. By 6 years, there is a global 
>90% neuronal loss. In some regions the retina is devoid of identifiable cells and replaced 
by unknown debris-like assemblies. Though the 6-year retina does have locations with 
iv 
recognizable neurons, all cell types are drastically reduced in number and some have 
altered metabolic phenotypes. These results are never seen in wt littermates, including 
rabbits which are 8 years old. Electron microscopic analysis using wide-field connectomics 
imaging of the 6-year TgP347L sample demonstrates some structurally normal synapses, 
indicating that survivor neurons in these regions are not quiescent despite the lack of 
sensory input for a substantial period of time. These results indicate that, although 
photoreceptor degeneration is the trigger, retinal remodeling ultimately gives way to 
neurodegeneration, which is a separate unrelenting disease process independent of the 
initial insult, closely resembling slow progressive CNS neurodegenerations. Indeed, both 
metabolic disruption and debris-related degeneration predicts the existence of a persistent 
neuropathy, and increases in α-synuclein levels support a proteinopathy component. 
Remodeling and neurodegeneration progress until the retina is devoid of recognizable cells. 
There is no stable state into which the retina settles and no cell type is spared. This has 
profound implications for current therapeutics. There will likely be critical windows for 
implementation but, ultimately, suspension of neurodegenerative remodeling will be 
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Diseases such as diabetic retinopathy, age-related macular degeneration, glaucoma, 
and retinitis pigmentosa, cause irreversible vision loss affecting millions of people 
worldwide.1 Of these diseases, degenerations that onset with the loss of photoreceptors 
(age-related macular degeneration and retinitis pigmentosa) have received special attention 
with the goal of restoring vision through therapeutic interventions, primarily after 
photoreceptors have degenerated.2-13 Ultimately this dissertation aims to describe the long 
term effects of retinal degeneration, factors contributing to degeneration following the loss 
of photoreceptors, identify potential complications in implementing therapeutics long-
term, and propose windows of degeneration in which therapeutic interventions have the 
greatest likelihood of success.  
 This chapter aims to introduce the reader to the structure of the healthy retina and 
its general roles in vision. In addition, this chapter will give a broad overview of retinal 
degenerative diseases, phases of degeneration, therapeutic interventions currently in 
development, and describe probable requirements for long-term vision restoration, which 





1.1 Architecture of the Retina 
The retina is a thin multilaminar strip of nervous tissue along the posterior surface 
of the eye, which developmentally originates from the frontal cortex, making it part of the 
central nervous system. The retina is subdivided into six major histological layers: the 
photoreceptor layer (which may be further subdivided into the outersegment, 
innersegment, and outer nuclear layer), the outer plexiform layer (OPL), the inner nuclear 
layer (INL), the inner plexiform layer (IPL), the ganglion cell layer (GCL), and the optic 
fiber layer (OFL) (Figure 1.1). It is composed of five major neuronal cell types: 
photoreceptors, horizontal cells, bipolar cells, amacrine cells, and ganglion cells.14 These 
cells working together play important roles in processing color, motion, intensity, and 
directionality from visual stimulus.15 In addition to neurons, the retina also has numerous 
glial cells: Müller cells, astrocytes, and microglia of immune system origin, providing 
critical functions in the retina. The retinal circuitry is primarily divided into two major 
pathways: vertical and horizontal. The vertical pathway is the path from the photoreceptors, 
bipolar cells, and ganglion cells, which ultimately project axons into the brain. It is 
primarily thought of as an amplification pathway, though the presence of ON and OFF 
cells permits the first level of light-detection processing, and ON-OFF motifs are preserved 
from bipolar cells through processing in the brain. The horizontal pathway tunes signals 
from the vertical pathway from being extremely broad regions of light detection to more 
defined regions of higher light intensity with less light intense regions surrounding. The 
higher intensity regions of focus are termed centers while the surrounding regions are aptly 
named the surround. Together, the vertical and horizontal pathways provide initial 




In most species, photoreceptors are the neurons of the retina found closest to the 
back of the eye. They are the first cells to receive visual stimulus via light, and consist of 
two major types: cones and rods. Rods and cones are responsible for translating light 
information (photons) into neurochemical signals, which is how most information is passed 
throughout the nervous system. In photoreceptors, the neurotransmitter released is 
glutamate. Mammals tend to have two to three types of cones and a single type of rod. The 
opsins (light-sensitive proteins) for both classes of photoreceptors are contained in the 
outersegment portion of the photoreceptor. Outer segments are composed of bilipid 
membrane stacked disks, which are continuously shed distally, and replaced proximal to 
the cell body. Rod outer segments are stacked in thin rod shaped columns, while cone outer 
segments are conical. Cones provide responses to bright light and have different opsins 
(light-sensing molecules) tuned to different wavelengths. The mixing of information from 
cones containing different opsins is the mechanism by which we see color. In contrast to 
cones, there is only one type of rod in mammals. Rods contain the opsin rhodopsin, and 
the rod transduction pathway makes it extremely sensitive to light, facilitating vision at low 
levels of light (e.g., starlight). A fundamental principle associated with all neurons is that 
when they are depolarized, the rate of synaptic vesicle fusion leading to neurotransmitter 
release is increased. When neurons are hyperpolarized the opposite is true. In response to 
light, photoreceptors hyperpolarize, meaning the amount of glutamate released decreases 
as the intensity of light increases. In darkness, photoreceptors are depolarized and 
constitutively release glutamate, leading to a large concentration of glutamate in the 
synaptic cleft. Though this may seem counterintuitive, the balance of glutamate being 
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released versus being removed from the synapse via transporters creates a concentration 
gradient making the system very sensitive to even small variations in light. The 
hyperpolarization and depolarization responses to photon capture are not an all-or-none 
response (e.g., an action potential), but rather a graded potential, allowing small and large 
changes in available photons to be rapidly relayed to neurons of the inner retina. The 
postsynaptic partners of photoreceptors (horizontal cells and bipolar cells) have evolved 
mechanisms to detect and respond to slight changes in glutamate release by photoreceptors. 
 
1.1.2 Horizontal Cells 
Horizontal cells are found immediately below the outer plexiform layer and, as the 
name would suggest, are oriented horizontal to the vertical pathway of the retina. The 
primary function of horizontal cells in most mammals is feedback onto cone photoreceptors 
helping to generate center-surround response curves and assist in tuning luminosity, though 
in nonmammalian vertebrates, they also help to tune chromatic information. Horizontal 
cells are extensively coupled to one another via large gap junctions, facilitating wide 
spreading of depolarization and hyperpolarization events throughout the retina. A common 
theme in neuroscience is sign-conserving versus sign-inverting synapses. Sign-conserving 
synapses are cases where the postsynaptic neuron has the same polarity response as the 
presynaptic neuron, though not necessarily the same kinetics. An example of this is the 
synapse between cones and horizontal cells. Horizontal cells are predominately activated 
via ionotropic glutamate receptors, which depolarize in response to glutamate released by 
cones and hyperpolarize when glutamate release is decreased, thereby matching the 
polarization state of the cones that directly drive them. In contrast, the “synapses” back 
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onto cones from horizontal cells are sign-inverting: as horizontal cells hyperpolarize, they 
trigger depolarization of the photoreceptor, albeit using nonconventional signaling 
pathways though to involve ephaptic mechanisms or alkalization of the perisynaptic space. 
These sign-inverting and sign-conserving feedback loops are a common motif that, 
combined with graded potentials, are fundamental to initial visual processing performed 
by the retina. The number and types of horizontal cells is variable between animals, but in 
mammals it is generally accepted that there are two types: type A (axon-less) and type B 
(axon-bearing). Despite the two morphological types, horizontal cells are often referred to 
as having three functional types; this is because the rod-associated axon terminals and 
cone-associated somas of type B cells function independently of one another. It is now 
thought that horizontal cell axon terminals may provide some feedback function for rods 
as well. The three functional types of horizontal cell’s feedback with photoreceptors create 
the first level of center-surround tuning. 
 
1.1.3 Bipolar Cells 
Bipolar cells are specialized interneurons, which pass signals from photoreceptors 
onto the rest of the retina. In mammals bipolar cells are subdivided into three major classes: 
ON-cone, OFF-cone, and rod. As described above, photoreceptors are persistently 
depolarized in darkness, and hyperpolarize in response to light. Bipolar cells respond to 
increases or decreases in light by either sign-conserving or sign-inverting responses via 
ionotropic glutamate receptors (iGluRs) or group III metabotropic glutamate receptors 
(mGluRs), respectively, on dendrites that synapse with photoreceptors within the OPL. 
Metabotropic glutamate receptors transduce sign-inverting signaling, which close cation 
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permeable channels in the plasma membrane in response to glutamate, decreasing inward 
currents and causing hyperpolarization. Alternatively, ionotropic glutamate receptors gate 
opening of cation channels in response to glutamate, increasing inward currants and initiate 
depolarization. Thus iGluRs mimick the response of the photoreceptors, leading to sign-
conserving signaling. ON-cone and rod bipolar cells express mGluR6 metabotropic 
glutamate receptors, causing them to depolarize in the presence of light. OFF-cone bipolar 
cells have ionotropic glutamate receptors, causing them to be depolarized in the absence of 
light. Bipolar cells, like photoreceptors, are glutamatergic in their neurotransmission to 
synaptic partners, with glutamate packaged into synaptic vesicles and associated with 
ribbon synapses in bipolar cell axons. Synaptic ribbons perform important tasks in 
amplifying signals from photoreceptors and pass the information to amacrine and ganglion 
cells either via AMPA receptors or a mixture of AMPA and NMDA receptors. Cone bipolar 
cells synapse directly onto ganglion cell dendrites, while rod bipolar cell axons do not.16 
Rod signals reach ganglion cells indirectly via the AII amacrine cell network. The layers 
of the retina where bipolar cells make their synaptic connections is mostly segregated: ON-
bipolar cells synapse in the proximal IPL (closer to the GCL), and OFF-bipolar cells 
synapse in the distal IPL (closer to the INL)17; although this is a generalization and some 
synaptic crossover does occur.18 
 
1.1.4 Amacrine Cells 
Amacrine cells play multiple roles in visual processing in the retina. They are the 
most diverse cell type in the retina, with the mammalian retina possessing at least 30 classes 
of amacrine cells. The main neurotransmitters associated with amacrine cells are GABA 
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and glycine.19-21 These neurotransmitters are inhibitory and they act on synapses in a sign-
inverting manner. In addition to chemical synapses, amacrine cells also couple with one 
another via a large network of gap junctions, permitting the transfer of graded potentials 
electrically. GABAergic amacrine cells are predominantly thought of as gain modulators 
of the retina helping to organize vision beyond ON versus OFF with a complex network of 
feedback synapses onto bipolar cells and feed forward synapses with ganglion cells. 
Beyond the synaptic contacts amacrine cells make onto bipolar and ganglion cells, one type 
of amacrine cell, the AII amacrine cell, plays a unique role in the vertical pathway as a 
sign-conserving interneuron. The AII amacrine cell receives sign-conserving synaptic 
input from the rod-bipolar cell axons causing it to depolarize. This depolarization then 
spreads to nearby ON-bipolar cells via gap junctions, leading to the depolarization and 
release of glutamate by these cells onto ganglion cells. Simultaneously, the depolarization 
of AII amacrine cells causes the release of the neurotransmitter glycine onto OFF-bipolar 
cells, thereby inhibiting them.16, 22 These two paths inject rod-ON and rod-OFF signals into 
ON and OFF ganglion cells, respectively. 
 
1.1.5 Ganglion Cells 
Ganglion cells are the only neuron of the retina to directly synapse within the brain. 
In mammals, ganglion cells project to the lateral geniculate nucleus, superior colliculus, 
suprachiasmatic nucleus, and accessory optic nuclei in the midbrain.23 The dendrites of 
ganglion cells arborize in the IPL and are postsynaptic to both bipolar cells and amacrine 
cells. Depending on the combination of bipolar and amacrine cell synapses onto ganglion 
cells and the spatial properties of the amacrine cells, different features of the visual world 
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are encoded into a sequence of action potentials to discreet nuclei in the brain. In addition 
to ganglion cells firing depending on whether they receive ON or OFF input, thereby 
preserving the initial encoding by bipolar cells, some ganglions cells are specially tuned to 
respond only to signals moving in certain directions, or are temporally responsive, giving 
transient or sustained responses to the same visual stimulus. Other ganglion cells are also 
intrinsically photosensitive due to their expression of melanopsin; these ganglion cells play 
important roles in the regulation of pupil size and maintenance of circadian rhythm.  
 
1.1.6 Glia 
Glia are traditionally referred to as the support cells of the nervous system. In the 
retina, the predominant glial cell type is the Müller cell. Müller glia have been shown to 
play important structural roles within the neural retina24 including sealing the retina off 
from the vitreous and separating the ONL from the INL. They play a key role in retinal 
homeostasis through removal of neural waste products such as CO2 and NH3, redistribution 
of K+, and are important in the glutamate-glutamine cycle by metabolizing glutamate to 
glutamine via the enzyme glutamine synthetase.25-27 The other macroglia found in the retina 
is astrocytes; they are predominantly restricted to the OFL, though they make some 
vascular contacts in the GCL, contributing to the blood-retinal-barrier (BRB). One 
distinction between brain astrocytes and retinal astrocytes is the absence of glutamine 
synthetase in astrocytes of the retina. In addition to macroglia, microglia may be found 
distributed throughout the retina, though they are typically found in the ONL, OPL, IPL, 
and GCL in healthy retina. In conditions of stress microglia may be found in different 
activation states throughout the retina.  
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In summary, the retina is a complex neural system, consisting of over 70 neural 
types (in mammals), which form chemical and electrical connections responsible for initial 
visual processing. The precise patterning of these connections, in addition to the metabolic 
system requirements to allow for constant signaling, work together to provide the brain 
with the information it needs to interpret the visual world. 
 
1.2 Retinal Degenerative Diseases 
Retinal degenerative diseases including retinitis pigmentosa (RP) and age-related 
macular degeneration (AMD) cause irreversible vision impairment, by directly or 
indirectly leading to photoreceptor loss. Though the initial progression rate of 
photoreceptor loss may vary between diseases, the ultimate outcome is the same: global 
loss of photoreceptors across the retina, leaving a deafferented neural retina. 
 
1.2.1 Retinitis Pigmentosa  
Retinitis pigmentosa (RP) refers to a range of hereditary disorders, which onset with 
degeneration of the photoreceptors. The name retinitis pigmentosa originates from the 
ophthalmoscopic observation of exposed pigmentation in the neural retina, arising from 
migration of pigmented RPE cells into the neural retina.28 The prevalence of RP is 
approximately 1 in 4000, with varying modes of inheritance: 50-60% of cases are inherited 
autosomal-recessive, 30-40% autosomal-dominant, and 5-15% X-linked. In fact, RP is 
known to arise from almost 300 gene defects,* which are subclassified by their genetic 
                                                 
* https://sph.uth.edu/Retnet/ (Accessed March 5th,2017) 
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component, mode of inheritance, and whether the defect is constrained to the eye or also 
affects nonocular tissues. Examples of associated nonocular diseases are Bardet-Biedl 
syndrome and Usher syndrome, which are both autosomal-recessive. Bardet-Biedl 
syndrome, in addition to photoreceptor loss, is associated with polydactyly, truncal obesity, 
hypogonadism, renal dysfunction, and learning difficulties.29 Usher syndrome is associated 
with hearing-loss in addition to RP.30 Despite the many modes of inheritance and genes 
involved with RP, outer segments of rod degenerate in a patchy fashion across the retina, 
followed by cones, and gradually lead to loss of vision in patients. 
The speed of vision loss and the mechanism causing the photoreceptor degeneration 
varies widely across RP diseases, along with the prevalence of that specific genetic defect. 
Some patients will present with vision loss early in life, while others will remain 
asymptomatic until mid-adulthood. In most cases, RP patients are legally blind by their 
mid-forties, and photoreceptor degeneration continues until the retina is completely devoid 
of photoreceptors, leaving patients completely unable to perceive light for years to decades 
of life.31 
 
1.2.2 Age-Related Macular Degeneration 
As the name would imply, Age-Related Macular Degeneration (AMD) 
predominately affects older people, and is the leading cause of vision loss in individuals 
over the age of 50.† Unlike RP, AMD is only partially associated with genetic inheritance. 
Rather, AMD is also associated with environmental factors such as smoking, which can 




greatly increase an individual’s risk.32 Clinically, patients often complain about blurriness 
in their central vision, which progresses to a loss of central vision which then advances 
outward towards the periphery.33 Histologically, dry AMD presents with drusen (lipid 
deposits under the retina) separating the RPE from the choroid, metabolic alterations of 
RPE cells,34 and subsequent stress and loss of photoreceptors. Wet AMD arises from new 
blood vessel formation (neovascularization) in the retina and subsequent leakage of blood 
and serum into the neural retina.  
 
1.3 Phases of Retinal Remodeling 
Early studies evaluating the progression of advanced RP in humans noted clear 
gliosis, cellular disorganization, and displaced RPE cells scattered around the neural 
retina.16 Other early ophthalmologists have also noted RP associated atrophy in humans, 
with an emphasis on an apparent loss of ganglion cells.35-36 These early observations 
however have not been recapitulated in animal models, and therefore have largely not been 
factored into strategies for therapeutic interventions.37 This was in part due to limitations 
of conventional histology and the result of short-lived experimental animal models. Recent 
post mortem studies of humans and the further extensive characterization of animal 
models38 have shown that neurons and glia of the retina undergo metabolic and 
morphologic remodeling as a key component of retinal degeneration, antecedent and 
subsequent to photoreceptor loss in both humans and animal models of RP.33, 37-40 
Remodeling includes neuronal rewiring, neurite growth, and reprogramming of neurons’ 
characteristic gene expression. Some remodeling begins as soon as photoreceptor stress is 
initiated, while other remodeling processes emerge following the complete regional loss of 
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photoreceptors. The phases of remodeling follow the loss of photoreceptors, so different 
regions of the retina are often in different phases of remodeling because photoreceptor loss 
appears in a patchy fashion in most instances. The description presented below assumes a 
rod-initiated RP-like process, but the long term progression, particularly in phase 3 
(described below), is similar in all forms.28 Ultimately, remodeling leads to large-scale 
corruption of neural networks in the retina, both through neural rewiring and cell death, 
making it unclear whether a retina which has undergone these alterations is capable of 
supporting therapeutic interventions to vision loss.41 In the interest of clarity, our lab has 
classified the extent of remodeling into 3 distinct phases (Figure 1.2).28, 40 
 
1.3.1 Phase 0: The Healthy Retina 
The healthy retina is described more completely in section 1.1 of this chapter. In 
brief, the retina is composed of two major components that will be referenced throughout 
this section: the sensory retina and the neural retina. The sensory retina is composed of the 
photoreceptors (both their outer segments and nuclei), which are responsible for the 
primary detection of light. The neural retina then performs extensive processing of the light 
information before transmitting the information to the brain via ganglion cell action 
potential. The neural retina is composed of five main cell types: horizontal cells (HCs), 
bipolar cells (BCs), amacrine cells (ACs), ganglion cells (GCs), and glia (predominantly 






1.3.2 Phase 1: Rod Degeneration 
Rod degenerations are triggered through a number of gene defects including those 
listed in section 1.2 of this chapter, or through some sort of trauma (retinal detachment or 
light-induced retinal degeneration). Regardless of the initiating insult, rod outer segments 
become shortened, followed by rod stress, deconstruction, and ultimately cell death. Prior 
to this, some rods will extend their axons and terminate in the GCL, rather than the 
conventional termination in the OPL.42 During the initial stress of the outer segments, rod 
bipolar cells begin to retract their dendrites from their previously associated rod terminal 
(spherule).43 Some of these rod bipolar cells will initiate rewiring and extend their dendrites 
toward cone terminals (pedicles).44 In addition, most or all rod bipolar cells change their 
expressed receptors from metabotropic to ionotropic, causing them to functionally change 
from being ON-type cells to OFF-type. Beyond the neural responses seen from the rod 
bipolar cells, glia also respond to the rod degeneration. Microglia begin to invade the 
subretinal space, presumably to aid in the removal of debris of rod degeneration. In the 
neural retina, Müller cells also respond to the stress signals by beginning to become 
hypertrophic and increasing expression of glial fibrillary acidic protein (GFAP), which is 
typically maintained at very low to undetectable levels in Müller cells of the healthy retina. 
In addition to GFAP increase, Müller cells also show a variable increase in glutathione 
levels, which is thought to be an indicator of oxidative stress.45 During the later period of 
rod degeneration, cones also begin to truncate their outer segments, even if the precipitating 
event was rod-specific. The mechanisms leading to the cone degeneration are currently 




1.3.3 Phase 2: Cone Degeneration 
As phase 1 remodeling transitions into phase 2, rods are continually degenerating, 
leading to a collapse of the outer nuclear layer and concurrently cone stress and 
degeneration. The main feature distinguishing phase 2 remodeling is the widespread death 
of photoreceptors.28 This process is likely the result of a number of factors, including 
microglial invasion of the subretinal space. RPE dysfunction caused by the rapid 
disassembly of rods, leading to debris accumulation in the subretinal space, is another 
theory for why cones die. The end result is the same; cones will degenerate and die, even 
in cases where the precipitating gene mutation is rod specific. This process may be fast or 
slow; there are forms of RP in which rod death causes cone outer segment loss, but the 
cone nuclei remain for extended periods of time, these are termed cone-sparing RP,47 and 
delay most late-stage remodeling as long as cones are present. When cones deconstruct, 
BCs retract their dendrites.43 HCs become hypertrophic and some extend multiple axon-
like processes into the neural retina, in some cases, reaching the GCL.48 Simultaneously, 
Müller cells elaborate a seal of their distal microvilli across the neural retina, gluing it 
together with intermediate junctions and fully separating the remnant cones from the 
RPE.37-38 Though there is some cell death in the neural retina during this period, it is a 
small and not seen in regular histological analysis.  
 
1.3.4 Early Phase 3: Neurite Remodeling 
The primary feature signaling the initiation of phase 3 remodeling is the loss of all 
photoreceptors. The preservation of even a small portion of cone cell bodies in a region of 
retina is sufficient to prevent much of the gross remodeling in that local region.38 As the 
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last of the cone cell bodies disappear, the glial seal separating the neural retina from the 
RPE completes, causing a total separation of the neural retina from the RPE and choroidal 
vasculature. In addition to the seal, Müller cells also hypertrophy along their trunks leading 
to the formation of large columns that fractionate the IPL,49 though the impacts of these 
elaborated columns on IPL connectivity is unknown, they appear to be conduits for 
neuronal migration.38 Cell death begins to become detectable within the neural retina by 
analysis of cell loss in phase 3, although the rate is so low that it cannot be tracked by 
techniques such as TUNEL labeling. At this point, anomalous neurites are produced by all 
classes of the remaining neurons. 
 
1.3.5 Mid Phase 3: Global Remodeling 
Following the extension of neurites by amacrine, bipolar, and ganglion cells into 
new neurite fascicles, many new neuron processes form de novo clusters of neurites that 
form new synapses between one another.38 These collections of synapses between ectopic 
neurites are termed microneuromas and contain pre- and postsynaptic structures from all 
cell types, though whether they maintain the selectivity seen in healthy retina is unknown. 
Some neurons translocate their cell bodies to ectopic locations throughout the retina (e.g., 
ganglion cells migrate to the distal retina and bipolar and amacrine cells migrate into the 
ganglion cell layer), though most of these translocations occur along the elaborated Müller 
columns that appear earlier in remodeling.38 Not all neurons survive this global remodeling, 
and there is a noticeable cell loss throughout the retina, with no apparent preference among 
any neural type. Throughout all of these changes, surviving neurons appear to maintain 
their core molecular signatures, regardless of positional location within the retina.38 
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1.3.6 Late Phase 3: Plateau Remodeling 
As phase 3 continues, cell death leads to a depleted neural retina, with all layers 
being reduced in cell number. Microneuromas persist, though they may decrease in volume 
due to loss of neurons.40 Müller cells break through the inner limiting membrane and form 
an epi-retinal membrane between the vitreous and the neural retina. The RPE begins to 
break apart and RPE cells can be found dispersed throughout the neural retina.38 
In summary, regardless of the primary insult, the neural retina undergoes a series 
of increasingly deleterious changes in response to loss of photoreceptors. These processes 
will likely have an impact on any therapeutic scheme introduced to restore/preserve vision 
once remodeling is initiated. Further understanding of these components will be essential 
to recommending the best potential therapeutic for different stages of remodeling.41 
 
1.4 Therapeutic Approaches to Vision Restoration 
A primary interest for current vision research is the advancement of new therapies 
for the treatment of photoreceptor-associated vision loss. Therapies including small 
electrode array implants to stimulate remaining neurons,2-4, 50 optogenetic approaches 
involving the transfection of specialized opsins into remnant neurons,6-7 and a number of 
genetic and cellular based approaches are currently being investigated.13, 51 Although these 
therapies may hold promise for future treatment of retinal degenerative diseases, it is 
difficult to fully assess their probability of success or improve upon the initial concept 







The fundamental concept behind optogenetics as a treatment for retinal 
degenerative disorders is that during and following the loss of outer segments of 
photoreceptors, if another cell type could be genetically encoded to detect light, vision 
could be rescued. Early studies demonstrated that when the algal channelrhodopsin-2 
(ChR2) is inserted into the membrane of mammalian cells, a depolarization event can be 
initiated via light52 and Archean halorhodopsin (NpHR) can induce hyperpolarization.53-55 
From this, the hypothesis was proposed that by genetically inserting these apoproteins into 
neurons, any neuron could be made light sensitive.56 Ultimately, the idea that neurons of 
the retina could be given new light detecting capabilities following the loss of 
photoreceptors57 was born. From here the discussion quickly turned to determining which 
cell type of the retina is optimal for targeting to induce, or restore, light-sensitivity. One 
early avenue was to restore light-sensitivity to cone somas, following the loss of outer 
segments with the goal of preserving native processing in the retina.5, 7 Though this has the 
caveat that in many forms of retinal degeneration, cone cell death occurs relatively early in 
the progression of the disease in humans, this may yet be a potential treatment in cases of 
cone-sparing RP. Subsequently, the neurons of the inner retina were targeted to compensate 
for the loss of photoreceptors, either through a broadly delivered intravitreal injection 
approach, which predominantly targets ganglion cells58-61 or through targeted delivery to 
specific cells of the inner retina.8, 12 The discussion is still ongoing which cell is the best 
for inducing light sensitivity, in what combination, and which are the best promoters for 
cell-specific targeting. A major problem with all the algal and protozoan opsins is their 
very low photosensitivity, requiring extremely bright light displays to generate responses.41 
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Some groups have demonstrated that native opsins, such as rhodopsin, transduced into 
mouse bipolar cells offer improved performance.62 Others have successfully transduced 
melanopsin into retinals, but the time course of melanopsin signaling is, so far, much too 
slow to provide functional vision.63 And of course virtually all of these studies are 
performed in retinas of mice in the very early stages of retinal degeneration, usually mid-
phase 2. 
 
1.4.2 Chemical Photoswitches 
A method for temporarily inducing photosensitivity in neurons involves the 
application of chemical photoswitches. These photosensitive small molecules regulate 
neuronal electrical activity by transiently blocking ion channels. An early study used the 
photochemical AAQ (acrylamide-azobenzene-quaternary ammonium), which in its trans 
form blocks K+ channels, thereby increasing excitability, and in its cis form unblocks K+ 
channels. AAQ photoisomerizes from its trans to cis conformation in the presence of short 
wavelength (~380nm) light, which unblocks K+ channels and decreases excitability. 
Relaxation from cis to trans occurs slowly in darkness, or reisomerization can be rapidly 
induced using long wavelength (~540nm) light,64 allowing bi-directional optical control. 
Polosukhina et al. unexpectedly found that 380nm light elicited action potentials, though 
K+ channels become unblocked at that wavelength. This turned out to be the result of AAQ 
primarily effecting amacrine cells, causing ganglion cells to fire due to disinhibition. A 
distinct problem with AAQ is the necessity of high intensity UV light for isomerization. 
Another chemical photoswitch that has been investigated is DENAQ (diethylamino-
azobenzene-quaternary ammonium).65  DENAQ is also a K+ channel photoswitch that 
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blocks K+ channels in its trans confirmation and unblocks in cis. A main difference is that 
DENAQ is red-shifted and photoisomerizes trans to cis within the visible spectrum (450-
550nm) then rapidly relaxes back to the trans conformation in the dark (within ~600msec).  
Also, DENAQ has been shown to be responsive to lower intensity light than either AAQ 
or many optogenetic strategies. Recently investigators have begun exploring new 
photoswitches capable of acting in AMPA receptors, via the photoswitchable excitatory 
amino acid (ATA).66 ATA is active in the dark, and photoisomerizes from trans to cis in 
blue light (480nm). The distribution of AMPA receptors causes a group of RGCs to 
respond to blue light, while another group fires in response to darkness.67 A combination 
of specific photoswitches may facilitate restoring ON-OFF responses, though remodeling 
leading to altered glutamate receptor expression levels will likely be of concern.68 
Photoswitches also demonstrate a shorter lifespan than optogenetics, which may make 
them a potential diagnostic tool.41 
 
1.4.3 Cellular Replacement Strategies 
In the majority of the central nervous system of mammals, once a neuron dies it is 
not replaced, which is the case in the mammalian retina. The advent of stem cell techniques 
brought with it the capabilities of differentiating new cells in vitro, with the hope of 
replacement of cells or entire organs grown specifically for an individual. Since the death 
of photoreceptors is the precipitating feature of all retinal degenerative diseases, 
photoreceptor replacement strategies are being investigated as a potential treatment. 
Photoreceptor transplants have had early success with surviving, for at least a few weeks, 
and have been found to generate synapses in the neural retina.69-70 It has been shown that 
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following introduction of embryonic stem cell derived photoreceptors, pupillary responses 
are increased in visually deficient mice,71 though it is unclear whether that is a response of 
photoreceptors or a change in the response of intrinsically-photosensitive retinal ganglion 
cells (ipRGCs). Further research is still ongoing to determine the long-term viability of 
transplanted cells and their functionality in the context of the total retina. In addition, our 
group has found that following the transplantation of fetal retina there is subsequent 
remodeling that occurs as fast as, or potentially faster than, that seen in degenerate retina 
without intervention.72 
 
1.4.4 Bionic Implants 
Beyond the biologic interventions currently being proposed, another methodology 
aims to intervene using principles similar to the widely successful cochlear implant; in this 
case, the retinal implant. Certain retinal implants, such as the Argus II epiretinal implant 
that is placed next to the ganglion cell layer in the vitreous, stimulate nearby neurons to 
fire action potentials in a pattern controlled by a video camera headset. This approach has 
the potential to provide for coarse vision, allowing increased independence and mobility 
among individuals affected by retinal degenerations.50, 73-74 There are two types of retinal 
implants: subretinal and epiretinal.3 A subretinal implant is surgically implanted under the 
retina between the photoreceptor layer (or former photoreceptor layer in the case of retinal 
degenerations) and the RPE, and uses thousands of microdiodes to generate light responses 
to be processed through the neural retina. An epiretinal implant is surgically placed along 
the ganglion cell layer of the retina, which does not require detachment of the retina from 
the RPE and generates action potentials in the associated ganglion cells based on images 
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from an external camera, bypassing neural retina processing. Both of these techniques have 
certain advantages. The subretinal implant has the capacity to utilize any circuitry 
remaining in the neural retina; however, as discussed in the remodeling section, it is likely 
that the circuitry of late retinal degenerations is corrupted. The epiretinal implant is 
currently in clinical trials (Argus II), which are showing distinct promise,73-75 although it 
is unable to mimic the wide variation in signals normally encoded by ganglions cells41 
(direction selectivity, ON versus OFF versus ON-OFF signals, and only minimal center-
surround responses).  
 
1.4.5 Genetic Approaches 
Among the therapeutic interventions for vision loss, genetic approaches are 
especially favored in cases where a specific gene defect is known to be the direct cause of 
vision loss. One such disorder is Leber’s Congenital Amaurosis (LCA), in which one form 
is specifically caused by a loss of function mutation in the RPE specific gene RPE-65. LCA 
is an early onset retinal degeneration, where affected individuals typically experience 
severe vision loss in the first few years of life. Gene-replacement therapy delivered via 
adeno-associated viruses (AAVs) has been used to introduce functional RPE-65, and has 
shown promise in restoring proper RPE function in animal models, especially the Briard 
dog76, and patients.77-81 Other gene therapies for replacing defective genes have been tested 
with x-linked mutations leading to RP with successful prevention of much of the early 
photoreceptor loss.82 A primary difficulty for the exclusive use of gene therapy to prevent 
or slow vision loss is the wide array of genetic defects that can lead to inherited retinal 
degenerations and the multiple environmental factors that contribute to the generation of 
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AMD.32 More importantly, intercession in most cases of recessive disease must occur 
perinatally, posing severe challenges for the medical ethics of early genetic manipulation. 
Also, many diseases are autosomal dominant in which a single defective gene can override 
the function of a normal gene and lead to photoreceptor death. Approaches to these 
disorders require suppression of the defective gene with methods such as shRNA targeting 
or new CRISPR/Cas9 gene editing methods. Even with these tools, there is currently no 
therapeutic path for human autosomal disease. While autosomal diseases tend to progress 
more slowly, extending into adulthood (via unknown mechanisms), it is not clear that the 
critical defect leading to widespread degeneration is operation of the defective gene per se 
or accumulation of toxic protein, in which case late intervention will be of little use. It is 
also important to note that despite the success of RPE65 gene therapy, the treated 
individuals still experience progressive cell death and slow rod kinetics83 which will 
require further research before the gene therapy can be deemed a full rescue.  
 
1.4.6 Requirements for Therapeutic Interventions to Be Effective 
The generation of therapeutic interventions and treatment for photoreceptor-
initiated vision loss is a lofty goal with a number of avenues of exploration. All therapeutic 
interventions require a functional neural retina. 
Therapies that hope to utilize the neural processing afforded by the inner retina have 
a number of difficult problems to overcome. Cell-replacement therapies are unlikely to 
result in long-term vision restoration or preservation unless the initial insult leading to 
photoreceptor degeneration is also directly treated. It also has not been shown that the 
synapses made by newly introduced photoreceptors produce the same visual acuity as 
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native photoreceptors (not even within an order of magnitude), nor have they been shown 
to persist. For most therapeutics targeted at stimulation of bipolar cells to be effective, 
regardless of whether via optogenetics, photoswitches, or subretinal implant, the primary 
circuitry of the retina must remain intact in addition to the metabolic support of surrounding 
glia. The basic idea that an epiretinal implant only stimulates ganglion cells, or that 
ganglion cells transduced by optogenetics or photoswitches could function independently 
is complicated by extensive coupling between ganglion cells and amacrine cells, as well as 
penetration of currents deep into retinal tissue. Previous data indicate that alterations in 
circuitry are present early in remodeling and it is unclear to what extent this affects the 
signals that are communicated to ganglion cells. We certainly know that retinal ganglion 
cells begin to display massive uncorrelated spiking in late phase 2.84-87 In addition, the early 
subtle variation of Müller cell metabolic phenotypes leads to questions regarding how 
widely Müller cells will vary with respect to one another, and how it will affect the 
metabolic support provided by Müller cells, particularly in the case of glutamate because 
excitotoxicity has been proposed as a potential contributing factor to retinal 
degeneration.25, 88-89 Clarifying these mechanisms is a goal of this dissertation. 
Retinal degenerative diseases have predominately been evaluated in rodent models, 
which have short life-spans, or shortly after the total loss of photo-receptors in large-eye 
model organisms. In contrast, humans live for decades with these disorders and are often 
functionally blind for years to decades of life. Many proposed interventions must target 
late-stage patients that are unable to perceive light, and some target ganglion cells with the 
assumption they will be the last remaining targets of intervention. We do not know the 
complete order or extent to which the neural retina deteriorates years after most 
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photoreceptors have died. Again, this dissertation will clarify much of that uncertainty. 
In summary, this dissertation aims to characterize the structural, biochemical, and 
metabolic changes in late-stage retinal remodeling years after all photoreceptors have 











Figure 1.2 Remodeling of the mammalian retina in retinal degenerations. (From Marc et 
al. 200337) Normal retina demonstrating proper lamination and organization of the 
mammalian retina. Some slight variations, such as vasculature, may vary with species. 
Phase 1 (a) shortening of rod outer segments. (b) Shortening of cone outer segments. (c) 
Initial death of rod soma. (d) Ectopic rod axons descending beyond opl. Phase 2 (e) 
Widespread rod death. (f) Loss of cone outer segments. (g) Ectopic neurite sprouting by 
amacrine cells. (h) Cone cell death. (i)Müller cell soma translocation. (j)Early stage of the 
glial seal. (k) Horizontal cell hypertrophy. (l) Horizontal cell neurite sprouting. (m+n) 
Bipolar cell dendritic retraction. Early Phase 3 (o) Fully formed glial seal. (p) Increased 
Müller cell hypertrophy. (q) Initial neural retina neuronal loss. (r) Neurite fascicle 
formation. (s) Early microneuroma formation. Mid Phase 3 (t) Increased multicellular 
fascicle formation. (u) Microneuroma growth. (v+w) Neuronal translocation. (x) 
Progressive cell death. Late Phase 3 (y) Regression of microneuromas due to cell death. 
(z) Progressive cell death. (aa) Continued Müller cell hypertrophy. (bb) Hypertrophy and 
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MATERIALS AND METHODS 
 
 The main body of the work presented in this dissertation relies on computational 
molecular phenotyping (CMP). CMP is a robust method for quantitative small molecule 
immunohistochemistry combined with cluster analysis to identify cell classes found in 
normal tissue, and identify metabolic variation in degenerative tissue. This chapter will 
introduce the animal model predominately used throughout this study. The background 
associated with the methods and model organism is extensive and presented in greater 
detail here to aid the reader in understanding the recurrent concepts underlying the body of 
work in the following chapters. 
 
2.1 Computational Molecular Phenotyping (CMP) 
Accurate classification of cells within biological systems is an important basic 
component of understanding how systems function. For decades the role of metabolism in 
cellular systems has been predominantly assessed using homogenates, which yields 
information about total concentrations of small molecules and enzymes across an entire 
tissue, but cannot divulge information about single cells, let alone interactions between 
cells. The nervous system is an exceedingly complex heterocellular system, in which small 
molecules act within cells and on neighboring cells through tightly regulated, cell-specific 
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mechanisms. Based on early studies in the late 1970s and early 1980s that demonstrated 
cells had combinations of neurotransmitters and neuropeptides at different levels within 
single cells,1-2 it stands to reason that the concentration of small molecules contained within 
the various cellular compartments might be unique to each morphologically and 
functionally distinct type of cell. This concept was formalized as the signature hypothesis 
in the 1980s, which posited that each morphologically and functionally unique type of 
neuron would also possess distinct neurochemical compositions.3-6 Computational 
molecular phenotyping is a robust method for harnessing the quantitative aspects of 
electron microscopy compatible, postembedding immunocytochemistry,7 and uses pattern 
recognition to classify cells into different cellular classes based on their signatures, which 
are defined by quantitative differences in small molecule concentration mixtures.8-10  
 
2.1.1 Molecular Trapping and IgG Labeling 
One of the predominant issues with respect to immunohistochemical detection of 
small molecules is the efficient trapping of small molecules in tissue. Formaldehyde 
(HCHO) is a 1-carbon small molecule that rapidly penetrates tissue and stops molecular 
interaction through aldehyde (-CHO) binding to terminal amines on specific proteins and 
small molecules. Formaldehyde is the traditional aldehyde for immunohistochemistry. 
However, its ability to cross-link protein amines via the formation of methylene bridges 
occurs relatively slowly; full formaldehyde cross-linking can take several weeks and even 
that is very sparse. Glutaraldehyde (HCO-(CH2)3-CHO), on the other hand, is a 5-carbon 
molecule, with a chain of three methylene groups and two aldehyde groups which rapidly 
bind with any available amine or imine via nucleophilic attack by N resulting in a Schiff’s 
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base formation. The increased number of carbons greatly increases the potential for cross-
linking, which generates a tightly cross-linked protein matrix.11 The generated matrix of 
glutaraldehyde conjugated amines can in turn bind to other free aldehydes via imine 
condensation, efficiently trapping small molecules quickly in cells. A potential 
complication of using solely glutaraldehyde in fixation is the two aldehyde groups. 
Assuming each glutaraldehyde molecule has a single aldehyde group binding an amine 
associated with protein, there will be an equal number of aldehyde groups available for 
small molecule binding. However, the number of free amines found in a cell is 
approximately 10 fold less than protein matrix amines, leaving a large number of unbound 
aldehyde groups. These unbound aldehyde groups will cause an increase in background 
due to nonspecific binding by antibodies.11 If solely formaldehyde fixation is used, the 
slow, and inefficient, cross-linking will cause a large percentage of small molecules to be 
lost during processing. Therefore, our solution is the use of a mixed aldehyde fixation 
protocol. By using 1% formaldehyde (333 mM, with 333 mM free aldehyde groups) and 
2.5% glutaraldehyde (250 mM, with 500 mM free aldehyde groups), small molecules are 
still effectively trapped while the total number of free aldehydes is reduced. Using a 
standard primary amine-secondary amine model12 of trapping where each amine N can 
capture two aldehyde carbons leads to a minimum of ≈ 84% capture by glutaraldehyde 
cross-linking, assuming no glutaraldehyde-formaldehyde exchange. But exchange is quite 
likely during Schiff’s base formation as the nucleophilic attack is strongly affected by water 
molecules at the condensation site and highly reversible under even neutral conditions. 
Assuming one switch event during condensation leads to 94% capture and two switches 
yields 97.5% amino acid capture, this is consistent with radiochemistry estimates 
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suggesting glutaraldehyde-formaldehyde mixtures lead to >86-95% retention of [3H]-
amino acids.13 
Immunoglobulins (IgGs) have been developed for detection of small molecules for 
almost a century. In the 1920s and 30s, Karl Landsteiner and colleagues performed 
pioneering research introducing the concept of haptens.14 Haptens, whether naturally 
occurring or synthetic, are small molecules that alone generate no immunological response, 
but when attached to a carrier molecule form a hapten-carrier adduct that is capable of 
initiating an immunological response. It is this concept that facilitates the generation of 
antibodies to small molecules such as amino acids. We harness this principle by using IgGs 
that have a high specificity to individual amino acid-glutaraldehyde adducts.15 
The protein matrix generated by glutaraldehyde cross-linking in cells has a mean 
pore diameter of 2-5nm as calculated simply from the size of glutaraldehyde. IgGs, on the 
other hand, are approximately 10x7x2nm, which precludes penetration of IgGs into 
glutaraldehyde-fixed tissue. This limits all epitope detection to the surface and makes small 
molecule detection proportional to the density presented on the section surface following 
surface etching to increase epitope mobility and IgG access. IgG binding is largely 
hydrogen bonding and requires hydrophilic regimes, so it is necessary to remove the plastic 
epoxide bond matrix. This feature of molecular trapping combined with surface labeling 
lends itself to direct quantification of small molecules found within a cell independent of 
section thickness. Tissue penetration by IgGs or ISH probes in frozen section or whole 
mounts, though helpful in detection of sparse proteins, results in uneven penetration of the 
antibodies into the various tissue compartments, making quantification impractical. The 
evaluation of small molecule concentration from these labeled sections is simple because 
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the available epitope density presenting on the surface of the section scales as a function 
of concentration (independent calculations‡).7, 15  
From the accurate small molecule trapping and IgG labeling described above,7, 9, 15 
we have one-dimensional information about the concentrations of amino acids contained 
within single cells in a tissue sample. The standard method for analysis of multiple antibody 
labeled cells in immunocytochemistry is by using multiple secondary antibodies 
conjugated to fluorophores reactive to different wavelengths. A key problem with 
fluorophores is bleaching, or the progressive decrease in brightness due singlet quenching, 
largely by intermolecular collision in the aqueous state. This makes fluorescent 
identification of small molecule concentrations in aqueous mounts nonarchival. Gold-
conjugated secondary antibodies or proteins binding to IgGs used in transmission electron 
microscopy, are archival16, but have the problem of being too small for easy detection by 
light microscopy at low density. Reverse-engineering the gold-toning method of 
photography, chemical reduction of silver nitrate to elemental silver particles plated on to 
gold particles was first applied to Western blotting techniques17 and then developed in the 
Marc lab for immunocytochemistry.15 In the presence of colloidal gold, the induction phase 
of hydroquinone reduced silver nitrate is drastically reduced, and the silver particles 
nucleate around the gold particle in a logarithmic fashion.18 This feature lends silver-
intensification to quantitative immunohistochemistry,15 allowing the concentration of 
silver particles to function as a direct logarithmic readout of intercellular small molecule 
concentrations. Marc et al., directly calibrated the method against HPLC determinations of 
                                                 
‡ http://marclab.org/technologies/cmp/cmp-substrates/  
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small molecules in retina.9 
 
2.1.2 CMP Analysis: Pattern Recognition 
The above section describes how we can obtain an archival quantitative measure of 
small molecules in a single section. Quantitative immunocytochemistry on thin sections 
allowed a direct test the signature hypothesis.9, 19-21 To apply these data to test the signature 
hypothesis, multiple small molecule signatures need to be evaluated simultaneously in 
single cells. The fact that IgG labeling for CMP is only surface binding, making section 
thickness irrelevant, lends it to using multiple thin sections through tissue and aligning 
them computationally. The smallest neuronal soma of the retina is the rod soma, which 
measures approximately 5µm in diameter (independent measurements from EM data). If 
the tissue were sectioned at 500nm, as in Ottersen’s experiments,7 10 IgG labeled sections 
could fit within a single cell; however, that would assume the first section was perfectly 
aligned with the edge of the cell, which is improbable. As serial sections are cut thinner, a 
single cell being able to be stained for up to 12 small molecules becomes increasingly more 
probable. For this reason, we cut samples (except where otherwise noted) at 100nm 
throughout this dissertation. Because these are individually cut sections, computational 
alignment of sections is necessary for multidimensional cell classification algorithms to be 
effective. Images of all molecular signals are acquired under constant gain and flux to allow 
for direct comparable quantification between metabolites. Images were aligned into a 
registered volume using nonlinear thin-plate-spline warping22 of selected chosen control 
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points. The primary tool was ir-tweak, available in ir-tools from the NCR§ toolset.9-10, 23-26 
Once in a registered volume, the multichannel dataset lends itself to pattern recognition via 
various clustering methods. 
By assigning each aligned grayscale image to a red, green, or blue color channel 
(rgb), we can visually identify the most dramatic differences between the metabolic 
signatures of major cell types and visualize the retina with more depth than traditional 
histology. However, this is not a statistical measure, and even with extensive rgb 
visualization of all possible combinations of all aligned images of IgG concentrations 
generated, we cannot accurately segment all of the metabolically distinct cells of the retina 
and one cannot see variance. Computationally, clustering (e.g. K-means or isodata) 
functions by similar principles: features are extracted from data and used by a classifier to 
subdivide the large mass of data into smaller data groups that share similar statistical 
features. These groups are termed classes. Rather than handling each IgG labeled registered 
image in isolation, duplicate, or triplicate, cluster analysis allows us to evaluate all N 
generated images simultaneously.  
Of clustering algorithms a popular unsupervised (i.e. no user directed training or 
sample classes) learning algorithm is k-means. K-means is a rapid method of separating 
input data into k clusters (groupings of similar points or data vectors) and has been 
extensively used in multispectral satellite imaging. We view each N-dimensional pixel 
representation as a data point in Euclidean space (N = individual image channels composed 
of an IgG labeled grayscale image) (Figure 2.1b). In its most common implementation, the 




k-means algorithm randomly assigns a set of k N-dimensional center points (centroids) in 
the data space, and decision boundaries are drawn between the centroids k (Figure 2.1c). 
All of the data points within each decision boundary are grouped, and the new mean of the 
points is computed, which becomes and new centroid. New boundary lines are computed 
from the new centroids (Figure 2.1d). The process of computing new centroids and 
boundaries are iterated until the movement of the centroid falls below a preset threshold, 
at which point the algorithm is said to converge (Figure 2.1e). The decision boundaries 
computed when a k-means converges determines the hypervolume containing the data 
points for each of the k regions, each denoting a metabolic class. We then remap the points 
back into the x,y conformation of a 2D image with colors assigned to its cluster 
membership, generating a theme map (Figure 2.1f). The theme map is then used as a mask 
for extracting individual histogram values of each small molecule, revealing its modal 
concentration in the class. In symmetrical unimodal histograms, the mode, median, and 
mean are the same. In general we summarize the data as spatial means, but the histogram 
always exists as the underlying dataset. The list of N small molecule means that define a 
class is termed its signature.  
Defining k can be a difficult task in the case of biological systems and, in fact, there 
is no formal method to extract the right k, nor is there an ideal clustering algorithm for all 
problems.27 We do not know a priori how many metabolically distinct cell types are 
possible, particularily in cases of pathology where the normal metabolic signatures of cells 
may have disappeared or diverged, but it is simple to compare k-means results using the 
same initial k, eliminating empty classes and comparing different classes. Visualization of 
cell-classes by representative theme-maps permits the identification of any inappropriate 
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classes arising from excessively stringent k values (e.g., differentiation of nucleus from 
cytoplasm within a single cell), and the emergence of over-clustering enables us to 
determine when the appropriate k for the sample has been reached. The classes produced 
are then tested for significant separability from one another using Bhattacharyya 
separability, which is a weighted measure of the degree of overlap between two statistical 
populations in N-dimensions. Over the course of this project, we found use of two other 
unsupervised clustering variants, similar to k-means, to be useful. One is an iteratively 
masking method, using custom software (CMP, Scientific Computing Institute, Salt Lake 
City, UT). Though the computational algorithm being run is k-means, it has the option to 
mask components not relevent to identification of metabolic classes (background, kerf, 
etc.). All k-means algorithms allow this, but CMP is particularly easy to use. This 
classification is run iteratively with k being incremented by 1 until it converges on statistics 
consistent with biological classes,9 that is, no subcellular fractionation. The second is the 
use of the isodata algorithm first used in neural classification by Marc and Jones, 2002.10 
Isodata starts out with a defined k and then merges or splits them based their mutual 
variances. Isodata is known as a heuristic or self-adjusting algorithm. In practice, data 
analysis starts CMP as a first screen, then switches to formal k-means (which has more 
parameter flexibility), and then switches to isodata if necessary. 
 
2.2 P347L Transgenic Rabbit Model of Retinitis Pigmentosa 
 The Tg P347L rabbit is a rabbit model of initially cone-sparing autosomal dominant 
retinitis pigmentosa (adRP) originally developed in the Kondo laboratory.28 Although there 
are a large number of animal models of retinal degeneration in drosophila,29-30 zebrafish,31 
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mouse,32-35 rat,36 chicken,37 cat,38-39 dog,40-41 and pig.42 medium sized animals with large 
eyes are extremely important for the development and testing of therapeutic interventions 
for retinal degenerative diseases. Testing surgical interventions, such as epi- or subretinal 
implants, particularly require a large eye model, and the costs of maintaining cats, dogs, or 
pigs can be prohibitively expensive. Rabbits provide a potential model organism of 
medium size, with an eye only ~25% smaller than that of a human.43-44 Harnessing the 
technology of bacterial artificial chromosomes (BACs), Kondo et al., generated a rabbit 
with a proline to leucine mutation caused by a C-to-T transition at proline 347 in exon 5 of 
the rabbit rhodopsin gene.28 This Tg P347L rabbit presents with a rod-dominant 
progressive photoreceptor degeneration, where rod photoreceptors display signs of 
degeneration and die prior to the degeneration and loss of cones. Like most transgenic 
models, the Tg P347L rabbit is an overexpression model with ≈ 6 copies of the defective 
gene.28 By 12 postnatal weeks, ERGs demonstrate a 72% reduction in scotopic a-wave 
(rod-response) amplitudes, and 95% reduction by 48 weeks. Under photopic conditions, a-
wave (cone-response) amplitudes persisted, though they did show a 65% reduction in 
amplitude.28 CMP combined with TEM demonstrated, in randomly selected regions, the 
P347L Tg rabbit has a profound loss of rod photoreceptors by 16 weeks, and a subsequent 
loss of cones by 40 weeks.23 At 40 weeks TEM reveals regional fluctuations in Müller cell 
polyribosome and protein levels, while CMP demonstrates glial seal formation, neurite 
outgrowth, glutamate receptor phenotype switching, and metabolic alterations.23 All of 
these changes are found in human RP.23-24  
Based on these previous studies detailing the early changes in the retina following 
rod loss and cone outer segment degeneration, the rabbit model is a likely candidate for 
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determining long-term consequences of photoreceptor degeneration and analyzing the 










Figure 2.1 K-means generation of theme maps. (b) N-dimensional pixel representation as 
a data point in Euclidean space. (c) K center points (centroids) are randomly placed in 
data and boundary lines are drawn. (d) All vectors within boundaries are averaged, and 
the centroids are moved to the average means. (e) The process is repeated until the 
centroids no longer move beyond a threshold in the averaging means step. (f) The 
clusters are then overlaid on top of the image stack and the clusters are used as masks to 
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 Müller cells are well known to play important roles in structural and metabolic 
processes of the retina. They provide central metabolic support to the surrounding cells, 
particularly in the glutamate cycle.1-2 Müller cells are the only cells of the retina which 
possess glutamine synthetase.2 In the primary glutamate cycle, glutamate is released from 
excitatory neurons and perisynaptic Müller cell processes transport the extra cellular 
glutamate into Müller cells, primarily via EAAT1 (excitatory amino acid transporter 1), 
also referred to as GLAST (glutamate/aspartate transporter).3 Upon entering the Müller 
cell, glutamine synthetase rapidly converts glutamate to glutamine by amidation. 
Following the conversion to glutamine within the Müller cell, glutamine is exported into 
the extracellular space by glial SN1.4-5 In all neurons, but especially in GABAergic and 
glutamatergic neurons, glutamine can be converted back to glutamate by glutaminase (EC 
3.5.1.2). Glutamate can now be loaded into vesicles via vesicular glutamate transporters 
(VGLUT) and released upon depolarization or converted to GABA by glutamate 
decarboxylase (EC 4.1.1.15) and loaded into vesicles via VGAT (which transports both 
GABA and glycine). The role of Müller glia is integral to both the extracellular glutamate 
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clearance and the synthesis of glutamate and GABA within the retina. 
Given this central role of Müller cells and glutamine synthetase in retinal glutamate 
metabolism, it is reasonable to expect that any disruption of this system could be 
detrimental to the maintenance of glutamate homeostasis in the retina. However, the role 
of Müller glia during retinal degeneration and whether the changes observed in the 
glutamate cycle are a cause or result of the degeneration are unclear and current topics of 
investigation. One popular hypothesis is the possibility of glutamate excitotoxicity in the 
retina contributing to neuronal degeneration of distressed retina.6-8 
 
4.1.1 Excitotoxicity Hypothesis 
One proposed mechanism of retinal degeneration is excitotoxicity-mediated 
degeneration. This concept was originally introduced by Lucas and Newhouse in 1957, 
where they demonstrated high levels of glutamate can be toxic to neural systems.9 
Excitotoxicity as a mechanism of not only brain injury, but as a factor contributing to neural 
death during retinal degeneration, has been supported by other studies.6-7, 10-11 A study that 
proposed a possible mechanism of excitotoxic injury was by Szatkowski, Barbour, and 
Attwell in 1990.12 They demonstrated that under conditions of high extracellular 
potassium, and high intracellular sodium and glutamate, a nonvesicular mechanism of 
glutamate release could be evoked from retinal Müller cells, indicating that Müller cells 
could potentially lose their capacity to adequately sequester glutamate away from neurons, 
which would be a likely component contributing to the development of an excitotoxic 
environment. 
Another study investigating the potential role of excitotoxicity in retinal 
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degeneration was conducted on the rd1 mouse.13 The rd1 mouse is a model of retinitis 
pigmentosa in which the mouse has early onset retinal degeneration, beginning with the 
loss (actually a failure to completely develop followed by cell death) of rod 
photoreceptors.14 Delyfer et al. used a chemiluminescence detection system to analyze the 
ratio of given amino acids to the total amino acid concentration.13 They found that the 
levels of glutamate, glutamine, and glycine were all significantly higher in the rd1 mouse 
than in the control. These data indicate a deficiency in the metabolism of core amino acids 
as degeneration progresses. Of importance to the question of glutamate-meditated 
excitotoxicity: Could the significant increase in the levels of glutamate within the 
degenerate retina could be contributing to the phase 2 photoreceptor degeneration or phase 
3 neuronal seen in the rd1 mouse? 
In addition to the aforementioned papers, which are primarily focused on the Müller 
glia’s ability to properly sequester glutamate, much of the excitotoxicity argument is based 
on ionotropic glutamate receptor associated toxicity. Ionotropic glutamate receptors 
(iGluRs) are postsynaptic ligand-gated ion channels, divided into three classes: N-methyl-
D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepionic acid (AMPA), and 
kainate (KA) receptors. AMPA and NMDA receptors are both calcium permeable when 
bound by glutamate (KA receptors are less Ca-permeant), and excessive calcium following 
sustained glutamate activation is thought to be the primary mechanism causing neural death 
in excitotoxicity.15 AMPA and KA receptors are often lumped together as ionotropic non-
NMDA receptors, as NMDA is an agonist at neither while KA and AMPA are agonists 
both, as is quisqualate. The effects of persistent AMPAR activation have been evaluated 
via KA administration. KA is a selective ionotropic glutamate receptor agonist, which 
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binds to KA receptors with high affinity and activates currents with fast desensitization, 
and binds with  lower affinity to more prevalent receptors, but does not desensitize, 
producing a sustained cation current.  Previous studies demonstrate that when KA is 
applied to the retina it greatly outcompetes glutamate for the AMPARs available on a large 
number of cell types within the retina, including but not limited to: starburst amacrine cells, 
AII amacrine cells, bipolar cells, and ganglion cells; sustained AMPAR sensitization can 
trigger apoptotic mechanisms.16 In addition to the studies into AMPARs potential role in 
mediating excitotoxicity, NMDARs have been implicated in contributing to neural death.17 
The sustained sensitization of NMDARs or AMPARs can lead to a prolonged increase in 
intracellular calcium within the cell, leading to cell death. 
 
4.1.2 Evidence Disputing Excitotoxicity 
The role of glutamine synthetase in the glutamate cycle of the neural retina was 
clearly shown by Pow and Robinson18 in which they used the suicide inhibitor D,L-
methionine D,L-sulphoximine (MSO) to inhibit glutamine synthetase (GS) activity in a 
normal rabbit retina. This demonstrated that following the inhibition of glutamine 
synthetase, bipolar and ganglion cells of the neural retina no longer exhibit any glutamate 
immunoreactivity (although the Marc lab has somewhat conflicting unpublished results). 
In contrast, Müller cells are extremely immunoreactive for glutamate as they no longer 
possess active GS to convert glutamate to glutamine. Of special interest to the question of 
excitotoxicity, they also tested the effect of increasing the extracellular levels of glutamate 
5 fold (35µM), and this also failed to elicit an increase in glutamate levels in bipolar or 
ganglion cells.  
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Marc et al. examined the role of the glutamate cycle in injury models of retinal 
degeneration using amino acid signatures of detached cat retina.19 Following detachment, 
Müller cells quickly lose their ability to convert glutamate to glutamine as seen by a 
decrease in Müller cell levels of glutamine and increases in glutamate. Consistent with the 
results of Pow and Robinson, this loss of apparent glutamine synthetase activity leads to a 
large increase in levels of intracellular glutamate in Müller cells (~5mM). Although 
glutamate concentration does later recover in neurons between days 6-30 of detachment, it 
is still substantially less glutamate than is found in neurons of the healthy retina and never 
regains normal levels. 
In addition to the alterations in glutamate-glutamine cycle in an injury model of 
retinal degeneration and remodeling, many immunocytochemical studies of metabolic 
changes have been performed on a variety of gene defect models of retinal degeneration.20-
22 In all of these studies there is a stereotypic pattern to the degeneration of the retina and 
the responses of the Müller cells, which are extremely similar to those seen in the injury 
induced model. Pfeiffer et al., showed a rise in the glutamine and glutamine synthetase 
levels in Müller cells.23 This rise in glutamine synthetase and glutamine subsequently 
dissipated as the retina continued to degenerate and remodel.24 Glutamate levels have been 
reported to either increase20 in Müller cells, or decrease.22 This inconsistency between 
studies is probably the result of variation in time points in addition to the large variability 
in amino acid signatures that can be observed between individual Müller cells in 
degenerated retina.20, 23, 25 The overall trend in the degenerate retina is a decline in neuronal 
glutamate and glutamine as the retina degenerates, however, it appears that following the 
initial decline there is some recovery, but it never again reaches normal levels. This 
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variability between Müller cells of glutamine, glutamate, and glutamine synthetase and its 
metabolic impact on surrounding retina warrants further investigation, however, none of 
these studies indicate excitotoxicity as a component of the degeneration.  
In this paper we examine the response of Müller cells to retinal degeneration over 
time, and whether the Müller cell metabolism alterations found in RP are likely to 
contribute to an excitotoxic mechanism of degeneration. Primarily identifying how the 
levels of glutamate and glutamine respond to the loss of glutamine synthetase during phase 
3 remodeling and degeneration, and how glutamate transport capabilities of Müller cells 
are affected. 
 
4.2 Materials and Methods 
4.2.1 Model Systems 
The transgenic rabbit model of autosomal dominant retinitis pigmentosa (Tg 
P347L), described in Chapters 2 and 3,24 was used for the assessment of metabolic 
variability using quantitative glutamine synthetase immunocytochemistry, quantitative 
CMP for glutamine, glutamate comparison analysis, and quantitative D-Aspartate loading. 
Six Tg rabbits spanning in ages from 1.5 years to 6+ years were used, with 3 wild-type (wt) 
littermates spanning 1.5 to 8 years used as controls. All animal experiments were conducted 
according to the ARVO Statement for the use of animals in ophthalmic and vision research 
with the supervision and approval of the Institutional Animal Care and Use Committee 
(IACUC) at the University of Utah. In addition, two human specimens, aged 21 and 77, 
diagnosed with RP were collected within 5 hours post mortem. RP tissues were obtained 
from two sources: The Foundation Fighting Blindness Retina Donor Program at Stanford 
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University and the University of Utah Lions Eye Bank. Genotyping of donors was not 
available and the mutations involved are unknown. Institutional approval for use of human 
eyes was obtained from the University of Utah and Stanford University and followed the 
tenets of the Declaration of Helsinki. All retinal tissues and data were de-identified in 
accordance with HIPPA Privacy Rules. These specimens were processed for CMP and 
used for analysis of variability.  
 
4.2.2 Tissue Processing 
Rabbit and human tissues were processed identically to those in Chapter 3, utilizing 
mixed aldehyde fixation for small molecules and proteins. In addition to the immediate 
fixation of many retinal samples, some retinas were processed for D-Aspartate (D-Asp) 
transport capabilities. In these cases, retinal chips ≈ 10-30 mm2 were transferred to 
cellulose acetate filter discs and bathed in 35°C Ames medium26 equilibrated with 95% 
O2/5% CO2 for 2-5 min. Following equilibration, some chips were then transferred to Ames 
media containing D-Aspartate (D-Asp) at 5 mM (a saturating level for EAATs), to evaluate 
the transport functions of Müller cells in the intact retina27 prior to fixation. All other chips 
were immediately transferred to mixed aldehyde fixation buffers. 
 
4.2.3 CMP Analysis 
CMP analysis of retinas was conducted as described in Chapter 3, which yields 
quantitative immunohistochemistry allowing us to directly compare levels of metabolites 
between samples. The previous chapters have described using k-means and isodata 
unsupervised classification to track the variability of Müller cells in representative fields. 
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In this study we sought to better understand the extent of the metabolic variability in 
degenerate retina. To fully characterize the metabolic changes occurring in Müller cells 
during degeneration, we argue it is necessary to quantify the number of Müller cell 
metabolic states in a selected sample. To perform this type clustering, a fusion version of 
unsupervised and supervised classification methods called intraclass separability analysis 
was used. First, the clusters of distinct Müller cell metabolic states generated from 
ISODATA classification were used to gain an idea of the total number of metabolic 
subclasses within the Müller cell class. Using this map, supervised classification using PCI 
Geomatica (Richmond Hill, Ontario, Canada) was performed as follows: Between 20-25 
seed points were set in the training component of supervised classification using raster 
seeding in which 6 input theme map channels were used (Taurine (τ), Glutamine 
Synthetase (GS), Glutamine (Q), Glutamate (E), Glutathione (J), and retinaldehyde-
binding protein 1 (CRALBP)). The pixel tolerance was set at 12 with an 8-connected 
neighborhood, allowing enough brightness variability to account for pixelation. From these 
seed points a Bhattacharyya Distance statistic was run on all seed points and any points 
with a separability of >1.9 were merged into a single metabolic class. A Bhattacharyya 
Distance of greater than 1.9 is equivalent to a p-value of <0.01. From this training channel, 
a maximum likelihood with a NULL class classification was run on the entire sample 
generating a theme map of the Müller cells and their separable metabolic variability.  
 
4.3 Results 
 Previous studies have shown Müller cells diverge from one another in an 
increasingly chaotic fashion,20, 24-25 however, the impact of this chaotic divergence and its 
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impact on the glutamate cycle is currently unknown. First, we demonstrate that the chaotic 
divergence of Müller cell metabolic signatures of rabbit retina is also present in human 
retinal degenerations (Figure 4.1). Levels of taurine, glutamine, and glutamate (red, green, 
and blue respectively), vary dramatically between Müller cells, including neighboring 
Müller cells as seen indicated by the red circle (Figure 4.1A). This variability continues 
throughout degeneration in rabbits (Figure 4.1B). It is also observed relatively early in 
humans (Figure 4.1C, 21 year old affected by recessive RP), and continues throughout RP 
progression (Figure 4.1D, 77 year old affected by unknown but likely dominant RP). This 
demonstrates that the variability found in rabbits is not unique. 
The observed variety of metabolic signatures in Müller cells led us to further 
classify the variability between Müller cell signatures within small regions of degenerate 
retina. Using intraclass separability analysis (see Section 4.2.3), Müller cells within a 
representative vertical region of intact retina classify into 6 metabolic states (Figure 4.2). 
This metabolic state separability is further distinguishable by Bhattacharyya distance 
(>1.9). The observed subclass separability is never found across the superclass of Müller 
cells in a normal retina, where only one class is known. It is of interest to note that these 
variable states do not occur as a continuum, which is expected if microenvironmental 
factors cause the variation. Rather all of the observed Müller cell subclasses appear 
independently of the metabolic states of their neighbors.  
As noted in previous descriptions of the metabolic alterations occurring during 
degeneration.23-25 GS levels are drastically lower throughout the degenerate retina (albeit 
to varying extents). This paradoxically occurs simultaneously with the observed global 
increase in glutamine and stable global concentration of Müller cell glutamate.24 This is in 
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stark contrast to the classic model that glutamate and glutamine levels in the retina are 
stoichiometrically related to the available GS activity. To determine whether this 
fundamental relationship is maintained despite the degeneration induced heterogeneity 
observed in Müller cells, we sampled n =5 Müller cells across both healthy and degenerate 
retinas and evaluated the relative amounts of glutamate, glutamine, and GS. In the healthy 
retinas, the levels of all three (and thus their ratios) remain constant. In the degenerate 
retinas, all three metabolites vary widely and independently of one another, conflicting 
with the standard model of glutamate-glutamine metabolism (Figure 4.3).  
It has been previously hypothesized that the decrease in GS is related to a loss in 
EAAT1 (the main E transporter found on Müller cells) found by the Reichenbach 
laboratory.28-29 To test this hypothesis we performed D-Aspartate loading both WT and 
TgP347L rabbit retinas. Until extremely late stages of degeneration, D-Asp loading, 
presumably by EAAT1, was fully functional in the degenerate retinas and capable of 
transporting any extracellular glutamate into Müller cells (Figure 4.4). In aged and 
neurodegenerate rabbit retinas (Figure 4.4D), some Müller cells appear to have lost 
glutamate transport capabilities (white arrows). We cannot yet explain the mechanisms 
allowing for the continued metabolism of glutamate and the increase in Müller cell 
glutamine, though it is probable that Müller cells with depressed GS activity unmask less 
commonly observed metabolic pathways. One potential unmasked mechanism is amidation 






4.4 Conclusions and Discussion 
  Three main conclusions may be drawn from this study. First, over the course of 
retinal degeneration, the chaotic phenotypes that appear in Müller cells not only vary with 
respect to one another, but diverge into multiple statistically separable metabolic classes. 
The impact of these states on the surrounding neurons warrants further study. Second, 
although GS is variably reduced in Müller cells across the retina in degeneration, its level 
appears to have minor impact on the levels of glutamate or glutamine within the same 
Müller cells. This implies the existence of a network-based metabolic homeostasis. Third, 
we see no evidence that Müller cell glutamate transport is drastically altered in response to 
the metabolic variability observed throughout degeneration, until the degeneration has 
advanced to a point in which it is unlikely there is a very high quantity of glutamate being 
released to need sequestration.  Previous suggestions that Müller cell glutamate transport 
fails early in retinal degenerations6-7 are unsupported by our data. Importantly, our analyses 
sample hundreds to thousands of adjacent Müller cells and there is no variation in 
glutamate transport until very late degeneration. Thus the conflicting results are not likely 
due to sampling differences.  
 These observations have several implications for retinal degeneration, particularly 
that arising from retinitis pigmentosa. As levels of GS have no correlated impact in 
glutamate or glutamine, concentrations within the Müller cells indicates GS is likely not 
the primary enzyme responsible for glutamate metabolism in the degenerated retina. Based 
on previous studies in the brain, this is not particularly surprising. This also conflicts with 
the acute studies of Pow,18 but it is important to recall that retinal degenerations are chronic 
steady states. Glutamate is a primary carbon skeleton that may be generated from multiple 
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enzymatic pathways and contributes to multiple other pathways. We argue that the 
glutamate-glutamine cycle should be considered less of a stoichiometric biochemical 
pathway and more of an intersection with many other metabolic pathways.30  The amount 
glutamate contributes to one pathway over another is likely to change depending on the 
metabolic demands of a cell, and in the case of glia, the requirements of the surrounding 
tissue. There is the caveat of the highly variable metabolic signatures found between Müller 
cells in close proximity to one another, which indicates a lack of microenvironmental 
influence over Müller cell metabolism. We do not know what drives the Müller cells to 
adopt such variability in their metabolic signatures, however to this end, we don’t know 
what causes the metabolism of Müller cells to be so homogeneous in the first place. This 
question will require further investigation of both healthy retinas and degenerate retinas.  
 A primary question this study sought to address is whether glutamate excitotoxicity 
is a likely mechanism contributing to the neurodegeneration observed in the inner retina 
following the loss of photoreceptors. In a more prosaic sense we ask whether the deaths of 
photoreceptors and any associated bursts of extracellular glutamate cells pose a challenge 
to cells that express iGluRs, that is, horizontal, OFF cone bipolar, amacrine and ganglion 
cells. Based on quantitative immunocytochemical methods of determining levels of 
glutamate within the intact retina, combined with the D-Asp transport results reported in 
this chapter, we do not find evidence that levels of extracellular glutamate are likely to rise 
for a sustained period of time. Although the traditional view of excitotoxicity has been 
largely regarded as a component of retinal degeneration, more recent studies,22 combined 
with ours, have largely called this view into question. For excitotoxicity to cause cell stress 
and death, sustained activity by high levels of glutamate are required, as well as expression 
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of iGluRs. Our results indicate that Müller cells continue to transport glutamate with no 
apparent change in Vmax long after neurodegeneration has greatly reduced the neural 
population of the retina. Although it is possible that there are local spikes in glutamate due 
to photoreceptor death, any downstream neuronal death would have to occur in minutes 
(rather than the reported days in the fastest models31) to potentially overwhelm functional 
Müller cell transport.32 Therefore we conclude glutamate-mediated excitotoxicity is not 













Figure 4.1 Müller cell metabolic variation across retinal regions and species. All are RGB registered projections of adjacent 
images of amino acid immunoreactivity; red = T, green = Q, and blue = E. Color variance in an individual image indicates 
varying ratios of TQE, and variance in concentration. A) Vertical section through central portion of rabbit retina. Arrows 
indicate select Müller cells demonstrating high variability. Ellipse highlights 5 Müller cells directly adjacent to one another all 
with varying metabolic profiles in comparison to their direct neighbor. B) Vertical section through peripheral region of 
TgP347L degenerate rabbit retina that has undergone massive remodeling and cell death. Arrows indicate Müller cells with 
varying metabolic profiles. C) Vertical section from a deceased 21yo male affected by early onset retinitis pigmentosa. Arrows 
indicate Müller cells, with varying levels of metabolites. D) Horizontal section of retina from 77 yo male affected by retinitis 






Figure 4.2: Müller cell metabolic variation within Müller cells. Base image is RGB registered projections of amino acid 
immunoreactivity with red = T, green = Q, and blue = E. Overlaid colors outlined in white are a representative mask based on 
the 6 Müller cell metabolic states a vertical section of Tg P347L retina. The mask was formed as described in the Methods 
section by intraclass separability analysis. Masks of similar color indicate metabolic states that are not highly separable from 
one another. Masks of differing color indicate that the metabolic states of the underlying Müller cell are significantly separable 




Figure 4.3 GS/Q/E variability in WT compared to degenerate retina. Images are RGB registered 
images of molecular immunoreactivity with red = GS, green = Q, and blue = E. Images are 
inverted to display intensity, similar to that of fluorescence. Colors in histogram plots are 
indicative of the same channel as in the RGB image. A) WT retina with 5 selected Müller cell 
regions. Pixel values for the sampled regions vary slightly, but the location of the individual 
peaks remains relatively constant indicating consistent concentrations of GS, Q, and E. B) 
Degenerate retina with 5 selected Müller cell regions. GS (in red) varies only slightly because the 
quantity of GS in this region of degenerate retina is extremely low. Despite the overall low 
concentrations of GS, the levels of E (blue) and Q (green) vary dramatically. Both may be higher 
or lower than is found in WT Müller cells, but variance does not appear to correlate with each 






Figure 4.4 D-Aspartate loading in retinal chips. Amino acid immunoreactivity from 
100nm sections of retina loaded in vitro by incubating immediately post-mortem with 
5mM D-Asp and subsequently fixing with 2.5% glutaraldehyde. Images are density 
scaled, meaning darker areas are indicative of greater D-Asp immunoreactivity and 
thereby greater D-Asp transport prior to fixation. White arrows indicate Müller cells with 
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LONG-TERM RETINAL DEGENERATION LEADS TO  
EXTENSIVE NEURODEGENERATION AND  
ALPHA SYNUCLEIN AGGREGATION 
 
5.1 Effects of Long-Term Remodeling on Therapeutic Interventions 
Retinal degenerations encompass many disorders that manifest with the death of 
photoreceptors leading to a loss of vision due to lack of sensory retinal input. Though some 
retinal degenerations are age-related, others may be early onset. In either case the affected 
individual is likely to suffer severe vision impairment for years or decades. Vision rescue 
of this population is an audacious goal, which many groups are pursuing through a variety 
of mechanisms. Cell replacement, genetic alteration, bionic implants, optogenetics, and 
stem cell therapy have all been proposed as possible mechanisms to restore vision 
following the loss of photoreceptors.1-6 However, the long-term impact and potential of 
each of these interventions cannot be adequately predicted without a full understanding of 
retinal remodeling of the inner retina following deafferentation.7  
There have been a number of proposed mechanisms contributing to remodeling and 
neuronal cell death in the inner retina associated with the loss of photoreceptors, including 
metabolic alterations,8-11 retinoic acid synthesis,12 changes in protein homeostasis,13 
oxidative stress, and changes in glucose metabolism.14 Protein aggregates are associated 
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with neurodegenerative diseases in the brain and have also been correlated to some retinal 
diseases where age is a primary risk factor (age-related macular degeneration and 
glaucoma).15 Although it is likely that a combination of the above mechanisms ultimately 
contribute to retinal remodeling, pathologic protein aggregation or proteinopathy is a 
probable central component of pathogenesis in retinal remodeling.  
 
5.2 Animal Models of Retinal Remodeling and Possible Caveats 
 Retinal remodeling is associated with loss of retinal input in both humans and 
animal models. A caveat in the current knowledge of retinal remodeling is that primarily 
short-lived animal models have been employed to evaluate the extent and components of 
remodeling.16 This causes a distinct disconnect between the experimental models of vision 
rescue and the ultimate goal of restoring sight in individuals who have severely remodeled 
inner retinas following years to decades of vision loss. In contrast to mouse or rat models 
of retinal degeneration (with mean lifespans of 700-800 days), the rhodopsin transgenic 
(Tg) P347L rabbit permits evaluation of retinal remodeling over many years (7-8y), 
recapitulating the remodeling observed in humans (see section 5.3.1).17 Using this model 
we evaluate late stage remodeling and mechanisms active long after the degeneration of 
photoreceptors is complete using computational molecular phenotyping (CMP),18 electron 
microscopy (EM), and immunohistochemical (IHC) analysis of proteins found to aggregate 






5.3 Materials and Methods  
5.3.1 Model Systems 
The Tg P347L rabbit is a rabbit model of cone sparing autosomal dominant retinitis 
pigmentosa (adRP) originally developed in the Kondo laboratory. It contains a rhodopsin 
proline 347 to leucine mutation that causes primary rod degeneration.17 Control rabbits 
were the unaffected littermates of Tg P347L rabbits (WT) (n = 7). We have previously 
characterized the progression of degeneration found in this rabbit, demonstrating the 
progression of degeneration in this rabbit follows the same trajectory of degeneration and 
subsequent remodeling seen in humans.9, 19-21 In brief, the P347L rabbit presents initially 
with rod photoreceptor degeneration and loss, though some rods survive up to 12-16 weeks, 
followed subsequently by progressive cone photoreceptor loss. By 40 weeks the majority 
of photoreceptors have degenerated and the inner retina is in varying states of phase 2 and 
3 remodeling. We expanded on the previous work by evaluating 10 Tg P347L rabbits 
spanning ages 3 mo to 6+ years for protein and metabolic changes.  
 
5.3.2 Tissue Processing 
Retinal samples were collected as previously described.22-23 All animal experiments 
were conducted according to the ARVO Statement for the use of animals in ophthalmic 
and vision research with the supervision and approval of the institutional animal care and 
use committee (IACUC) at the University of Utah. Animals were euthanized with urethane, 
isoflurane, or pentobarbital (depending on USDA guidelines at the time of experiment), 
followed by bilateral thoracotomy. Following euthanasia, tissues were cut into smaller 
pieces and split between 3 fixative solutions: 
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1. 2.5% glutaraldehyde solution (2.5%FGMg) used for quantification: 2.5% 
glutaraldehyde, 1% formaldehyde, 0.1M phosphate buffer (pH 7.4), 1 mM 
MgSO4, 3% sucrose.  
2. 4% formaldehyde solution (4%F) used for initial antibody testing and 
protein expression pattern identification: 4% formaldehyde, 0.1M 
phosphate buffer (pH 7.4), 1 mM MgSO4, 3% sucrose.  
3. Cacodylate glutaraldehyde solution (2.5%Cac) for ultrastructural analysis 
by transmission electron microscopy (TEM). 2.5% glutaraldehyde, 1% 
formaldehyde, 0.1M cacodylate buffer (pH 7.4), 1 mM MgSO4, 3% sucrose.  
All tissues for CMP and TEM were processed as previously described.18, 24-25 In 
addition to the small molecules used for CMP described below in section 5.3.3, we used 
glutaraldehyde tolerant antibodies to full protein α-synuclein (α-syn), phosphorylated α-
synuclein (P-α-syn), Ubiquitin (Ubi), phosphorylated tau protein (tau), and β-amyloid. For 
a full list of antibodies used see Table 1. 
 
5.3.3 Computational Molecular Phenotyping (CMP) 
We used CMP for the identification of cell classes and quantified the changes in 
protein levels of the inner retina.18, 25-26 Each well of the array slide was probed for an IgG 
for 1 of 6 small molecules: aspartate (D), glutamate (E), glycine (G), glutamine (Q), taurine 
(τ), or GABA (γ). All primary antibodies were probed with a gold conjugated secondary 
then silver intensified for 6.5mins on a 30°C plate.18, 27 Slides were then captured as 8-bit 
images using a QImaging Retina CCD camera (Surrey, BC) under constant gain and offset. 
The grayscale images were then computationally aligned using ir-tweak,28 generating a 
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registered volume where each grayscale image is an individual metabolite. We used 
computational clustering (isodata) to define class signatures (PCI Geomatica), which 
allows cells to be separated into metabolically relevant cell classes according to small 
molecule signals.27, 29 Cell classes are then represented as a theme map, in which each color 
represents a single statistical cell class. These theme maps can then be used for masking all 
but a single cell type and evaluating the associated protein expression, or can be overlaid 
on traditional TEM images.10, 25 In addition to theme maps, molecular signals are also 
viewed in triplicate combinations using red, green, and blue (rgb). For example, τQErgb 
assigns taurine, glutamine, and glutamate to red, green, and blue channels, respectively. 
 
5.3.4 Protein Variation Quantification 
In addition to the small molecules used for identifying cell classes present in tissue, 
we used a number of antibodies for the identification, localization, and relative 
concentration of proteins. Proteins probed for were: glutamine synthetase (GS), GFAP, 
phosphorylated ser129 alpha-synuclein (Pα-syn), alpha-synuclein (α-syn), ubiquitin (ubi), 
tau, beta-amyloid (β-amy), rhodopsin (1D4), and tomato-lectin (TL). Relative protein 
concentrations were calculated by probing the tissue stacks with monoclonal rhodopsin 
antibody 1D4 in addition to proteins of interest. Based on our experience using CMP with 
small molecules, we extended the approach to also include proteins, by using the known 
concentration of rhodopsin (5 mM) and the known efficacy of 1D430 to estimate the levels 
of each of the proteins over time. In addition, we performed Western blot analysis to further 
validate our observations of increases in α-syn in Tg retinas. Briefly, dissected retinas were 
homogenized, and then solubilized in lysis buffer.31-32 After sonication, homogenates were 
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centrifuged for 15min at 12000 rpm, supernatant transferred to new tubes, and total protein 
content was measured by the Bio-Rad Bradford protein assay. 20µg of protein was 
incubated at room temperature for at least 30 mins with Laemmli sample buffer [50mM 
Tris-HCL, 2% SDS, 100mM DTT, and 10% glycerol], separated on a 15% SDS gel and 
transferred to a PVDF membrane in transfer buffer. Blots were blocked using 5% dried 
milk, 0.1% Tween diluted in TBS (TBST). Blots were probed using anti-α-syn (1:2000) 
and anti-actin (1:2000) overnight at 4°C. Membranes were washed 3x in 5% dried milk in 
TBST (~5 mins each) and incubated in either goat-anti-mouse or goat-anti-chicken IgGs at 
a concentration of 1:2000 for 1 hr at room temperature. Membranes were washed 2x in 5% 
dried milk in TBST followed by 3x in TBST (~5min each). The blots were exposed to film 
after SuperSignal chemiluminescent substrate treatment (Pierce, Rockford IL) and imaged 
by FluorChem Q with AlphaInnotech AlphaView software (Cell Biosciences, Inc., Santa 
Clara, CA, USA). 
 
5.4 Characterization of Aged P347L Rabbit  
By 40 weeks of age the Tg P347L rabbit retina is largely devoid of rod and cone 
outer segments and has an extremely depressed ERG (80% scotopic a- and b-wave 
reduction, and 70% photopic a and b wave reduction.17 During years 2-4 the retina 
manifests a total loss of photoreceptor nuclei in a patchy fashion. Ultimately, with the loss 
of cones, the retina enters into phase 3 remodeling (Figure 5.1A-C). Although it was 
previously assumed (with little evidence) that the retina would enter into a state of 
equilibrium at this level of remodeling, CMP analysis of retinas from 2-, 4-, 5-, and 6-year-
old degenerate retinas show pronounced loss of glutamine synthetase (GS) (Figure 5.2 
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A,D,G,J,M), high levels of metabolic heterogeneity between neighboring Müller cells, and 
increased levels of anatomical remodeling most notably in their endfeet (Figure 5.2 
B,E,H,K,N). This continuum of metabolic revision and structural remodeling continues 
until the Müller cells have no recognizable metabolic signature or form, but are 
transformed into thick, overlapping blocks of glia or replaced by a debris-like assemblies 
filling large areas of the remnant retina (Figure 5.2 C,F,I,L,O). In tandem with the Müller 
cell alterations and ultimate degeneration in aged Tg P347L rabbits, neurons of all types 
have been lost, exceeding 90% in some areas. Though a large number of neurons were 
absent by 6 years, some identifiable neurons remained and these were of particular interest. 
To evaluate their potential to be long term survivors despite the breakdown of the 
surrounding retina, we combined CMP with TEM imaging which allows us to map the 
main molecular classes of cell types in TEM images (see materials and methods). In these 
zones we examined, virtually all of the remnant ganglion cell somas and processes 
displayed severe cytoplasmic pathologies, apparent proteins aggregates and/or massive 
internal vesicle accumulations (Figure 5.3). This led us to explore some of the possible 
molecular markers of similar pathologies found in CNS neurodegenerations.  
 
5.5 Ubiquitin Expression in Retinal Degeneration 
 The severe late-stage remodeling in the Tg P347L rabbit, including pronounced cell 
death, metabolic variation, and debris accumulation, is reminiscent of protein aggregation 
associated with neurodegenerative diseases. For initial evaluation we assessed ubiquitin 
levels and localization as a measure of protein degradation and aggregation. Soon after the 
onset of outer segment stress and degeneration levels of ubiquitin are increased in nuclei 
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of the ONL, with focal patchy increases within ganglion cells (Figure 5.4B). Following the 
loss of the outer segments, but prior to the complete loss of the ONL (~2yr), ubiquitin 
levels appear stable, with continued low expression in remnant cones, some cells of the 
INL, focal expression in ganglion cells, and the beginnings of expression in the optic fiber 
(Figure 5.4C). By 3-4 years, along with the complete loss of the ONL, ubiquitin expression 
is dramatically increased in neurons of the inner retina (Figure 5.4D). At 5 years the 
ubiquitin is found to be patchy in its expression. Some cells have low levels, but regional 
aggregates appear, which are difficult to assign to intracellular or extracellular 
compartments (Figure 5.4E). At 6 years the ubiquitin localization remains patchy, similar 
to that seen at 5 years (Figure 5.4F).  
 
5.6 Alpha Synuclein Aggregation in Older Transgenic Retina 
 Given these variations in ubiquitin expression and localization, we hypothesized 
some other proteins were likely involved in remodeling, perhaps those found in slow CNS 
neurodegenerations. We evaluated the location and expression of α-synuclein (α-syn), β-
amyloid, tau phosphorylated at T231, and α-synuclein phosphorylated at locus at S129 (Pα-
syn), which is associated with oligomerization. Evaluation of transgenic retinas spanning 
in age from 3 months through 6 years using protein CMP revealed no aggregation or 
specialized localization of phosphorylated tau or β-amyloid in the P347L rabbit (data not 
shown). In contrast, α-syn and Pα-syn showed marked changes in expression and 
localization as remodeling progressed (Figure 5.5). In WT tissues α-syn is found 
throughout the retina, with higher levels found in rod outer segments33 and the ONL, than 
in neurons or the IPL of the inner retina. Pα-syn is found at low levels distributed in neurons 
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of the ONL and the INL, along with some signals in fibers and nuclei of the ganglion cell 
layer. In Tg retinas, the levels of both α-syn and Pα-syn vary with age and level of 
remodeling present in the retina. Although the signals may vary depending on the level of 
remodeling in a given region, the basic pattern is as follows: Early in degeneration (3mo-
1.5yrs) levels of α-syn are roughly equal to that found in WT, with higher levels found in 
the outer segments of degenerating rods and lower levels throughout neurons of the outer 
and inner retina. Pα-syn is dramatically increased in horizontal cells, along with a more 
subtle uniform increase in the INL, IPL, and GCL. By ~2yrs the thinned ONL shows high 
levels of α-syn, with increased concentrations in the inner retina as well. Of note, at this 
stage the α-syn in ganglion cells appears to no longer be uniformly distributed, but rather 
is aggregated along the outer cell membrane. Extracellular aggregation of Pα-syn around 
and within some ganglion cells emerges. At ~4yrs degeneration the ONL is largely absent 
and α-syn is found solely distributed in the nuclei of the inner retina, with some punctate 
staining distributed within the IPL, presumable at large synapses. Pα-syn levels are two-
fold higher than α-syn throughout neurons of the inner retina. Pα-syn has also begun to 
aggregate inside cells, particularly ganglion cells. At 5yrs the Pα-syn continues to 
aggregate within ganglion cells, in addition to displaced neurons found within the IPL, and 
at high concentrations in many INL soma. α-syn is found highly expressed in all remaining 
cells and is predominantly colocalized with high levels of Pα-syn, with an exception of 
punctate levels in the IPL as IPL staining is unique to the full protein. By 6-7yrs the 
structure of the retina is severely decimated. α-syn is distributed widely throughout 
remnant cells and processes of the retina. Pα-syn is not only ubiquitous in the remaining 
neurons but is also found in aggregates in the cellular debris making up much of the 
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remnant retina. Combined, these data indicate α-syn overall increases throughout 
degeneration while there is a pronounced increase and eventual aggregation of Pα-syn. In 
support of these data, Western blot analysis reveals a two-fold increase in monomeric α-
syn at 4 years of degeneration in P347L rabbit retina, and continual increase to five-fold 
by 5 years, which is consistent with data from Parkinson’s disease suggesting that native 
cytosolic multimers shift to a monomeric form as a mechanism of disease initiation.34 In 
contrast, there is no increase in a-syn in wt rabbit even at 8 years of age, indicating this 
increase in α-syn is not age-dependent (Figure 5.6). In order to confirm the effects seen in 
our Western Blot and histological analysis, we performed a blocking experiment, which 
demonstrated that the antibodies are specific for Pα-syn and α-syn (Figure 5.7). 
 
5.7 Discussion 
 By evaluating structural, ultrastructural, metabolic, and protein alterations in 
advanced age TgP347L rabbit retinas we characterize late retinal remodeling as a 
neurodegenerative proteinopathy. Based on these data we conclude that the previously 
reported plateau of remodeling in experimental animals and its extrapolation to humans is 
incorrect and due to incomplete data produced by the short lifespan of rodents.  
This development in our understanding of retinal remodeling presents both new 
hurdles and opportunities to the vision community and neuroscience as a whole. 
Progressive neurodegeneration and glial deconstruction after the complete loss of 
photoreceptors suggests that optogenetic and photoswitch interventions are destined to fail 
in all patients long term, regardless of their initial mechanism of photoreceptor loss. 
Similarly, cell regenerative approaches using stem cells or differentiated cellular 
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replacement are also futile because proteinopathy, as in the CNS, likely does not respect 
cellular origins. A particularly potent example of this the accumulation of pathologic levels 
of a-syn in some fetal nigral transplants in Parkinson’s disease.35 
Our discovery of retinal remodeling as a neurodegenerative proteinopathy also 
affords a number of opportunities to the neurodegeneration community. The retina is 
unrivaled by any other area of the CNS in its accessibility and our understanding of the 
associated metabolism and circuitry. These factors combined make the remodeled retina 
an attractive candidate organ for the discovery of pathways leading to α-synuclein 
aggregation and ways to prevent or reverse it36 in Parkinson’s disease, Lewy-body 
dementia, multiple-system atrophy, and other α-synuclein associated neurodegenerations.  
In the short term this has two primary impacts on research: First, groups interested 
in success in treating retinal degenerations need to devote more resources to generating 
interventions that prevent or delay the onset of remodeling, such as blocking retinoic acid 
activation of neuritogenesis.12 Second, it is imperative that at least as many resources are 
devoted to basic research understanding the development of proteinopathies and 
neurodegeneration as translational therapeutics. Without basic research understanding all 
of the primary components leading to diseases like neurodegeneration, the vast majority of 




Table 1. Immunocytochemistry reagents 
 
 
Reagent RRID Source Dilution 
anti-D-aspartate 
IgG 
NA Signature Immunologics 1:100 
anti-L-aspartate 
IgG 
AB_2341093 Signature Immunologics 1:100 
anti-L-glutamate 
IgG 
AB_2532055 Signature Immunologics 1:100 
anti-glycine IgG AB_2532057 Signature Immunologics 1:100 
anti-glutathione 
IgG 
AB_2532058 Signature Immunologics 1:100 
anti-L-glutamine 
IgG 
AB_2532059 Signature Immunologics 1:100 
anti-taurine IgG AB_2532060 Signature Immunologics 1:100 
anti-GABA IgG AB_2532061 Signature Immunologics 1:100 
anti-GABA IgY AB_2532062 Signature Immunologics 1:100 
anti-GS IgG AB_397879 BD Biosciences  1:50 
anti-CRALBP 
IgG 




Anti-α-syn pS129 NA AbCam ab184674 1:500 
Anti-α-syn (pan) NA AbCam ab190376 1:2000 




Figure 5.1 Representative registered images of amino acid immunoreactivity in 100nm 
sections of WT, Phase 2, and Phase 3 remodeling in rabbit retinas. 1A) γGE rgb of a WT 
rabbit retina. The lamination of outer segments (OS), outer nuclear layer (ONL), inner 
nuclear layer (INL), inner plexiform layer (IPL), and ganglion cell layer (GCL) are all 
clearly laminated. 1B) γGE rgb of a TgP347L degenerate rabbit retina currently in phase 
2 remodeling. The yellow circles demonstrate examples of remaining cone cell bodies, 
although the majority of the OS and ONL is absent. 1C) γGE rgb of a TgP347L 
degenerate rabbit retina in phase 3 remodeling. White arrows indicate amacrine cells, 
which have translocated from their appropriate position either into the IPL, or have moved 
apically towards the remnant RPE. Inlaid density scaled images demonstrate aberrant 




Figure 5.2 Representative images from WT rabbit (A-C), 2yr (D-F), 4yr (G-I), 5yr (J-L), and 
6yr (M-O) Tg P347L rabbit retina. 2A) WT retina stained for glutamine synthetase (GS) 
showing strong staining throughout Müller cell and their endfeet 2B) WT retina stained for 
tomato lectin (TL) stains the extra cellular matrix (ECM) allowing the inference of cellular 
compartments. 2C) τQE  rgb sCMP of a WT rabbit retina. This combination of amino acid 
facilitates the visualization of most major cell types in the retina. Müller cells appear yellowish-
orange in this configuration (indicated by the oval). Ganglion cells appear teal (upward white 
arrow). Amacrine cells are pink or green immediately adjacent to the IPL (examples 
demonstrated by black upward arrows). Bipolar cells are the cells of varying shades of pink 
above the amacrine cells (black horizontal arrows). Horizontal cells are the dull green cells at 
the border between the ONL and INL (downward white arrows). 2D) GS staining of a 2yr 
P347L rabbit retina. GS staining shows a global decrease in GS levels, but a nonuniform 
pattern of decrease between neighboring Müller cells. 2E) TL staining of 2yr Tg P347L rabbit 
retina. The extra cellular matrix stain visualizes the increase in the fingerlike projections of the 
Müller cell endfeet. Also there is a thinning in the external limiting membrane and the predicted 
decrease in nuclei in the outer nuclear layer following the loss of outer segments. 2F) τQE  
rgb sCMP of a 2yr Tg P347L rabbit retina. The outer segments and outernuclear layer have 
degenerated, though a few cone cell bodies remain (examples indicated by yellow circles). 
Müller cells, although similar, have diverged in metabolic profile as indicated by the varying 
colors of orangeish-yellow (brackets). Müller cell hypertrophy is also visible at this stage 
(oval). 2G) GS staining of 4yr Tg P347L rabbit retina. At this stage of degeneration GS has 
dropped to almost undetectable levels. It is likely that using conventional fluorescent staining, 
this level of GS would be indistinguishable from background fluorescence. 2H) TL staining of 
a 4yr P347L rabbit retina. The majority loss of the outernuclear layer is now leading to more 
aberrant architecture of the Müller glial endfeet. In addition to the continual development of 
finger-like projections the Müller cell endfeet appear to have become intertwined with some 
large stalks pushing the IPL out of its normal lamination. The outer limiting membrane has 
also continued to break down. 2I) τQE  rgb sCMP of a 4yr Tg P347L rabbit retina. Müller 
cells demonstrate a complete loss of metabolic homogeneity, as demonstrated by the range of 
colors. The IPL is pushed apically in some regions (white arrows) while it is pushed basally in 
others (black arrows). 2J) GS staining of a 5yr Tg P347L rabbit retina. GS levels remain 
markedly lower than WT, with more prominent staining along apical region of retina. 2K) TL 
staining of a 5yr Tg P347L rabbit retina. ECM staining continues to show the elaboration of 
intertwined Müller cell projections throughout the GCL, where endfeet once resided. Indicated 
by a circle is a point in which the basement membrane appears to be breached by some 
components of the inner retina. 2L) τQE  rgb sCMP of a 5yr Tg P347L rabbit retina. The 
endfoot region of the Müller glia has expanded to double its original size, while the metabolism 
has not returned to a homogeneous population as evident by the range of orange, brown, and 
green. Holes have begun to form in some regions, likely due to compromised aquaporin access 
to the vitreous. The number of neuronal nuclei has decreased, and lamination in the INL is 
unclear. 2M) GS staining of a 6yr Tg P347L rabbit retina. GS expression is still at an almost 
undetectable level. 2N) TL staining of a 6yr Tg P347L rabbit retina. The ECM staining 
demonstrates a lack of identifiable retinal structure beyond a few cell nuclei. 2O) τQE  rgb 
sCMP of a 6-7yr Tg P347L rabbit retina. The former GCL has now tripled in size, but has only 
remnants of processes likely to have arisen from ganglion cells. The sole remaining ganglion 
cell in this region has migrated into the IPL. Some glial-like signatures remain, but they appear 
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drastically altered from those found in WT retina. Intermixed with the glia, there are regions 











Figure 5.3 Theme map overlay of TEM image of retina. 3A) Theme map generated via k-means clustering of a 6-7yr Tg P347L 
rabbit retina. Metabolic signatures used for clustering: E, Q, J, D, G, γ, τ, and GS. Purple theme class indicates ganglion cells 
(GCs), while dark blue in the GCL layer indicates the theme class containing ganglion cell processes. 3B) TEM close-up of large 
ganglion cell found in the middle of the IPL. Swirl structures are indicative of autophagy. 3C) Magnified TEM image of multiple 
GC processes in intermediate stage of autophagy. 3D) Magnified TEM image of another GC process almost entirely filled with 
autophagy-associated swirl structures. 3E) Magnified TEM image of another GC without autophagic swirl structures. Inset 






Figure 5.4: Grayscale ubiquitin labeling in rabbit retinas. 4A) WT P347L littermate control 
demonstrating light ubiquitin immunoreactivity distributed around Müller cells. 4B) 3mo 
Tg P347L rabbit retina demonstrating increased expression in ONL and some ganglion 
cells. 4C) 2yr Tg P347L rabbit retina with moderate levels in nuclei of inner retina. 4D) 
4yr Tg P347L rabbit retina. Levels of ubiquitin have risen in soma of the INL and GCL.4E) 
5yr Tg P347L rabbit retina, demonstrating variable level of ubiquitin across all cell types. 
4F) 6yr Tg P347L rabbit retina. Levels of ubiquitin in probable debris is patchy. The 








Figure 5.5 Endogenous signaling of phosphorylated α-synuclein (Pα-syn), full protein α-
synuclein (α-syn), and GFAP. 5A-C) WT rabbit retina. A) Pα-syn, α-syn, GFAP  RGB 
mapped B) grayscale Pα-syn and C) grayscale Pα-syn, demonstrating normal expression 
pattern of Pα-syn and α-syn in the absence of significant stress (indicated by absence of 
GFAP). 5D-F) 3mo Tg P347L rabbit retina. D) Pα-syn, α-syn, GFAP  RGB mapped E) 
grayscale Pα-syn and F) grayscale Pα-syn, during early phase 1 retinal remodeling. The 
largest change is the presence of Pα-syn in the horizontal cells (HCs) indicated by black 
arrows. 5G-I) 2yr Tg P347L rabbit retina. G) Pα-syn, α-syn, GFAP  RGB mapped H) 
grayscale Pα-syn and I) grayscale Pα-syn, during early phase 2. The largest change is the 
emergence of Pα-syn outside of ganglion cells (GCs) indicated by a red circle. 5J-L) 4yr 
Tg P347L rabbit retina. J) Pα-syn, α-syn, GFAP  RGB mapped K) grayscale Pα-syn and 
L) grayscale Pα-syn, during late phase 2 retinal remodeling (prior to loss of remnant cones). 
As the ONL disappears, levels of Pα-syn begin to dramatically increase in the INL and 
GCL with more diffuse phosphorylated aggregates being found throughout the GCL 
(downward facing arrows). 5M-O) 5yr Tg P347L rabbit retina. M) Pα-syn, α-syn, GFAP 
 RGB mapped N) grayscale Pα-syn, during phase 3 retinal remodeling (no remnant 
photoreceptors). Increased Pα-syn in cells of INL and GCL. In GCs Pα-syn begins to 
strongly aggregate along outer cell membrane. 5P-R) 6yr Tg P347L rabbit retina. P) Pα-
syn, α-syn, GFAP  RGB mapped Q) grayscale Pα-syn and R) grayscale Pα-syn, during 
the most advanced phase 3 retinal remodeling seen to date. Increased Pα-syn in all 











Figure 5.6 Western Blot: Beta actin demonstrated some increase in Tg retinas when 
compared to WT. α-synuclein demonstrated 2-fold increase at the 4 year time point and 




Figure 5.7 Antibody inhibition experiment. A) Pα-syn, without block. B) α-syn without 
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DISCUSSION AND FUTURE DIRECTIONS 
 
The purpose of this project was to understand the long-term effects of retinal 
remodeling on the neural retina and use this data to gauge likelihood of long-term success 
of different therapeutic interventions in late-stage degeneration. At the time of the project’s 
inception, the belief in the field (including our laboratory) was that the degenerate neural 
retina would eventually hit a plateau phase of remodeling, where microneuromas would be 
prevalent with significant changes in retinal circuitry, some cell loss will have occurred, 
Müller glia will be altered, and RPE will have infiltrated, but that the neural retina will 
continue to survive in that remodeled state. The simple conclusion to be drawn from this 
project is that there is no such plateau in remodeling. Remodeling progresses long after 
photoreceptors have died but eventually gives way to a full neurodegeneration phenotype 
apparently similar to CNS neurodegenerations.  
 
6.1 Müller Cell Metabolic Chaos 
 The first key finding of this project was significant alterations in Müller cell 
metabolism during late phase 3 remodeling. In aged human retinas, it is common to find 
variable levels of glutathione across Müller cells, which intuitively makes sense given its 
role in buffering against cellular damage caused by reactive oxygen species, with which 
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we come in regular contact, and given the varied experiences of normal humans (smoking, 
inflammation, obesity, alcoholism, stress, circadian variations, etc.,) However, in addition 
to glutathione, the increases in variability of glutamate, glutamine, taurine, and glutamine 
synthetase in Müller cells, as was found in degenerate retina, was unanticipated. If such 
changes were driven by the microenvironment, that is, if hypertrophic Müller cell columns 
changed their metabolic, gene, and protein expression in response to environmental cues 
generated by regional differences in photoreceptor degeneration, we would expect to find 
Müller cell metabolic variation along a gradient centered on regions of photoreceptor 
degeneration. This is not what we observe. Adjacent Müller cells appear to have individual 
metabolic profiles that vary irrespective of their surrounding environment in retinal 
degeneration. There are a number of avenues for investigation into the source of these 
changes. 
First, we hypothesize a Müller cell synchrony signal that regulates metabolism and 
synchronizes cells across the normal retina. We expect that it will function based on a 
number of factors present within the intact retina, perhaps additional photoreceptor signals 
such as melatonin1 or endothelin, as first described by Rattner and Nathans.2 Many studies 
attempting to identify potential factors leading to Müller cell regulation use dissociated 
Müller cells.3-8 If we are correct in our hypothesis that Müller cells are somehow 
synchronously regulated, dissociated cells are likely to express differing phenotypes than 
those found in vivo. In fact, gene expression studies have indicated heterogeneity in 
dissociated mouse Müller cells.7 Even anatomical studies on dissociated cells3 may result 
in misleading information. Though the level of diversity in Müller cells and the potential 
for multiple types is still in debate for adult Müller cells, it is likely that they do respond to 
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circadian rhythm. Müller cells have vasopressin receptors, which facilitate their response 
to the circadian variations in vasopressin secretion by some amacrine cells.9 From this it is 
possible that there are circadian variations in Müller cell metabolism, but these potential 
variations would be expected to occur across the retina, not differentially in individual 
Müller cells. We have evaluated the small molecule signatures of many thousands of 
Müller cells from hundreds of samples, generated from dozens of species, and all normal 
retinas display a stereotyped τ+Q+E- signature with exceedingly low variances between 
Müller cells. This indicates that despite possible genetic and anatomic variations between 
cells, regulating those metabolites within a narrow range is important to Müller cell 
function.  
Second, in healthy retina we observe a clear formal tiling of the endfeet of Müller 
cells. In healthy retina, the processes originating from a Müller cell column do not 
intertwine with the processes from adjacent Müller cells, nor do Müller cell endfeet 
overlap. This motif is lost in degenerating retina (Chapter 5). Müller cell endfeet begin to 
invaginate to form finger-like projections that encroach upon neighboring Müller cells 
domains. It is unknown if this process is also occurring more apically as the Müller cells 
hypertrophy. This phenomenon of glial morphology variation coinciding with metabolic 
variability during neurodegeneration is not without parallel in the brain.10 McKee et al. 
found that following repeated head injury astrocytic processes hypertrophied and became 
intertwined.11 The impact of glial entanglement is currently unclear, however, its 
coincidence with high levels of metabolic variability raises a question of whether the 
tangles themselves may affect the metabolic interactions between neurons and glia and 
contribute to the variability. 
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These hypotheses are not exclusive. Both may play a role in the metabolic 
disruption seen throughout retinal degeneration, in addition to currently unidentified 
factors. Determining the functional impact of metabolic and anatomic disruption 
throughout retinal degeneration is still an ongoing question that will require further 
research in the future. 
 
6.2 Excitotoxicity in the Retina 
 The concept of excitotoxicity in the brain is extensively cited in the field of 
neuroscience.12-13 In the retina, it has been proposed that increased glutamate contributes 
to excitotoxicity in the retina during retinal degeneration.14-15 For this to happen, glutamate 
near neurites expressing iGluRs must reach a concentration high enough to cause neuronal 
stress and death. Although glutamate was shown to be toxic and induce lesions in the retina 
of young mice in 195716 and was replicated through the 1960s,17-18 it is important to 
consider what concentration of glutamate was used. Lucas and Newhouse report that to 
produce a lesion with a single subcutaneous injection they needed a near-lethal glutamate 
level, and to avoid this multiple smaller injections were given.16 Still, these were increasing 
concentrations from 2mg to 30mg of L-glutamate per day, with a maximum concentration 
of 150M. For reference, the average retina has a total glutamate concentration of 1.5 mM;19 
with some ganglion cells containing the highest level of glutamate, ~10mM, bipolar cells 
ranging from 1-5 mM, and photoreceptors containing 1 mM or less depending on 
adaptation state. Glutamate is not transported across the blood retinal barrier or blood brain 
barrier at physiological levels,20 it is possible the lesions seen in retina may have been 
caused by a separate mechanism, such as ischemia from particulate21 or RBC22 aggregates 
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following high glutamate exposure, rather than from the added glutamate directly. More 
recent studies have demonstrated that if the extracellular concentration is raised above 30-
100µM and maintained there for a couple of hours it is sufficient to induce Müller cell 
swelling and some neuronal stress,23 though these results are not consistent with previous 
literature24 or any of our findings. In any case, a large number of glutamate-containing cells 
would have to die in a single region in an exceedingly short period of time (on the order of 
minutes), and extracellular glutamate would need to remain at that concentration for hours 
to induce an excitotoxic effect. To this end, the rate that Müller cells can transport 
glutamate away from neurons is of interest. Data from our lab have shown that the Müller 
cells continually buffer up to approximately 5mM extracellular glutamate,25 more than 3 
times the total glutamate of the retina.26 
Therefore, for glutamate excitotoxicity to potentially contribute to the 
neurodegeneration seen in the retina, there would have to be significant disruption of 
glutamate transport by the Müller cells. It has been demonstrated conclusively in Chapter 
4 of this dissertation that glutamate transport by the Müller cells is not significantly 
disrupted until very late stages of retinal degeneration, and most of that is in single Müller 
cells, not widespread populations. The timepoint at which the Müller cell transport begins 
to be widely compromised is in our 6-year-old rabbit, which has already undergone 
massive cell loss. Based on this, it is unlikely that glutamate excitotoxicity plays any 
significant role in retinal degeneration and future drugs or therapies based on this premise 
(e.g., neuroprotective glutamate receptor antagonists) are likely to have no effect on the 




6.3 Retinal Neurodegeneration 
  During the course of retinal degeneration it is clear that both remodeling and 
neurodegeneration play important but differential roles in determining the final state of the 
neural retina. Previous studies evaluated the neural retina up to a year after the loss of 
photoreceptors.27 Based on our analysis in Chapter 5, we conclude that retinal remodeling 
and neurodegeneration are separate overlapping processes occurring over the course of 
retinal degeneration (illustrated in Figure 6.1). Retinal remodeling begins in tandem with 
the loss of photoreceptors, and is characterized by progressive receptor alteration, neurite 
sprouting (followed by microneuroma formation), and early metabolic variation.27-35 
Retinal neurodegeneration on the other hand is what leads to the eventual decimation of 
the retina, and is characterized by metabolic chaos36 and collapse within Müller cells, 
widespread cell death, debris accumulation, and likely has a proteinopathy component as 
evident by an increase in α-synuclein. Neurodegeneration begins after photoreceptors are 
lost and eventually supersedes remodeling years after the photoreceptors were lost, and 
continuing until the retina is entirely devoid of recognizable cells. Although this 
development is unfortunate for late-stage therapeutic interventions, this opens up a new 
potential for evaluating early disease progression in other synucleinopathies. Within the 
brain, neurodegenerative proteinopathies propagate slowly throughout affected regions 
following modifications of certain proteins making them prone to misfolding and 
aggregation.37 One such protein is alpha-synuclein, which is associated with multiple 
neurodegenerative diseases.38-40 Multiple mechanisms of alpha synuclein toxicity have 
been proposed, including proteasome impairment and stress, mitochondrial dysfunctions, 
ER stress, and membrane disruption and pore formation.41 During the course of 
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degeneration, we see ultrastructural evidence for mitochondrial and ER stress. The 
increases seen in ubiquitin aggregation in the nuclei could also be attributed to the ubiquitin 
proteasome system being impaired.42 All of these processes are slow progressing in the 
brain. We see similar signs of neurodegeneration occurring in the retina combined with 
focal increases in alpha synuclein. We posit that these processes are likely to occur at an 
accelerated rate in the retina in comparison to the brain in large part due to the close 
proximity of neurons to one another and relatively short axons, which can facilitate 
transneuronal propagation in a shorter time frame than that seen in the brain.  
 
6.4 Implications for Therapeutic Interventions 
 Taken together, these findings show that the best time to intervene in retinal 
degenerative disease is as early as possible. When a specific genetic mutation is known, 
gene-replacement therapy shows the best promise for preventing widespread photoreceptor 
degeneration. Immediately following the onset of photoreceptor degeneration, 
optogenetics or photoswitches may be capable of restoring some, albeit coarse, vision to 
help provide independence; though complications due to rewiring will have to be addressed 
(see section 6.5, Future Directions). Later in disease, epi-retinal bionic implants may be a 
solution to bypass corrupted retinal circuits, though glial separation of ganglion cells from 
the vitreous and the progressive loss of ganglion cells will be an obstacle. However, Loizos 
et al. have shown by modeling that it is unlikely that epiretinal implants only stimulate 
ganglion cells.43 It is unlikely that photoreceptor or whole retina replacement therapy will 
ever be the best choice. Photoreceptor replacement will always depend on our ability to 
prevent remodeling or even death of the transplanted cells,44 and if we have that capability 
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the cellular replacements will likely be unnecessary. Whole retina replacement requires the 
ability to properly rewire the ganglion cell axons correctly to targets in the brain, which is 
an independently exceedingly difficult and probably insurmountable challenge. From the 
potential postphotoreceptor degeneration interventions, one fact is clear:  preventing 
neurodegeneration progression will be crucial to long-term vision maintenance.   
 
6.5 Future Directions 
Based on our assessment of neurodegeneration being a large obstacle to late state 
retinal degeneration, we propose that the best timepoint for intervention will be as soon as 
possible after diagnosis. Because it is common for considerable photoreceptor loss to have 
occurred prior to a patient seeking treatment, remodeling will likely have already altered 
neural circuits in the inner retina. Prior studies have demonstrated neurite sprouting, with 
molecular markers indicative of active synapses,33, 45 however, it remains to be seen 
whether the network topology of this system is correct. The synaptic and gap junction 
partners of neurons remaining in the retina during remodeling have not been addressed. To 
fully determine the extent of network alterations in the degenerating retina and their 
potential impacts on signaling capabilities of the remodeling retina, it will be necessary to 
construct connectomes for varying phases of remodeling and neurodegeneration. We have 
generated a preliminary pathoconnectome volume (RPC1) that combines the high 
resolution ultrastructure of automated TEM with the quantitative aspects of CMP, and is 
the first pathoconnectome ever generated. RPC1 consists of 948 serial sections spanning 
from the proximal ONL to the vitreous, with 1 of every 30 sections reserved for CMP data 
that are intercalated into the volume. In brief, sections were serially sectioned at 90nm and 
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prepared for TEM capture or CMP analysis. The resolution afforded by TEM is vastly 
superior to serial block face scanning electron microscopy (SBFSEM).46 Our standard 
TEM acquisitions have a resolution of 2.18 nm/pixel, and because the grids are archival, 
we have the ability to reimage structures at a resolution of 0.27 nm/pixel. Alternatively, 
SBFSEM has a published resolution of 8-16 nm, which is too coarse to positively identify 
gap junctions or small synapses.47 CMP lends itself to positive cell identification through 
classification enabled by the quantitation of small molecules,19, 25, 48-50 which are 
stoichiometrically trapped during fixation,19, 48, 51 in addition to glutaraldehyde/osmium-
tolerant IgGs. For the identification of all cell structures and genetically labeled cells in the 
volumes we will use a combination of small molecule IgGs to GABA, glutamate, 
glutamine, glycine, and taurine, in addition to IgGs targeting GFAP, GFP/YFP, TH, 
Tomato lectin and GS. RPC1 was assembled using a modified version of the NCR toolkit**. 
Briefly, the toolkit combines individual images acquired from a JEOL electron microscope 
with a 16-Mpixel Gatan camera (EM sections) or a Leica light-microscope affixed with 8-
bit CCD camera (CMP) and registers them into assembled mosaics before using automated 
registration to align adjacent sections throughout the volume (Figure 6.2).46-47 Following 
the assembly of the connectome volume, navigation and annotation of the dataset will be 
done in the software Viking, which facilitates rapid navigation, visualization, and 
annotation of TEM and CMP data.52 Viking annotations retain information about the size, 
structure, location, and may be queried for population statistics.47, 53 From a Viking-
annotated dataset, we can render 2D and 3D representations of cell including their 




subcellular components (e.g., pre- and postsynaptic densities, organelles, gap junctions, 
etc.).54  
 Preliminary data reveal three distinct phenomena in early degeneration (10mo old 
P347L rabbit retina). First, dendritic structures of rod bipolar cells are significantly altered 
indicating the initiation of dendritic remodeling (Figure 6.3A) likely associated with 
reprogramming described by Marc et al.35 Annotation of these dendrites will allow us to 
determine what combinations of photoreceptors contribute to the inputs of rod bipolar cells 
during the loss of rod photoreceptors. Second, by tracking neurite outgrowths from bipolar 
cells (that Marc et al., argued were supernumerary axons) it is clear that many of the ribbon 
synapses generated therein are morphologically altered (Figure 6.3B). The evaluation of 
these ribbons and their synaptic partners may yield insights regarding revised networks of 
the inner retina. Third, although it has been previously observed that high levels of electron 
density (presumed to be hyperosmication due to high levels of ribosomes, RNAs, 
aromatics, or unsaturated fatty acids) in Müller cells of degenerating retina, we had 
previously described it in the primary trunk. It is now clear that hyperosmication also 
appears in the finest processes of a Müller cell as it encroaches on a neighboring Müller 
cell’s domain (Figure 6.3C). Continued evaluation of the ultrastructure of the Müller cells, 
combined with metabolic information afforded by CMP, will allow us to further evaluate 








Figure 6.1 Retinal degeneration, a combination of remodeling and neurodegenerative 
processes. Retinal remodeling consists of the processes undergone by the retina in initial 
response to photoreceptor loss. In phase 1, rods begin to degenerate, and Rod bipolar cells 
retract their dendrites from rod spherules. Phase 2 continues the loss of photoreceptors with 
the loss of cone outer segments and complete loss of rods. Phase 2 is also characterized by 
initial metabolic variability seen in Müller cells. Phase 3 is initiated by the complete loss 
of photoreceptors. In the remodeling processes, neurite sprouting is abundant and leads to 
microneuroma formation. While remodeling continues to progress long after 
photoreceptors are absent, neurodegeneration processes eventually overwhelm the remnant 
neural retina. Retinal neurodegeneration is characterized by a complete lack of Müller cell 
coordination and increased α-syn in remaining neurons. As these initial processes persist, 
cell death occurs over large parts of the retina and coincides with debris accumulation. The 
timeline demonstrates the increasing impact of retinal neurodegeneration over the lifespan 
of rabbit and mouse. It is probable that mice do not live long enough for the end stages of 



















Figure 6.2 Workflow for generation of pathoconnectome. a) Tissue from a 10 month Tg P347L rabbit retina was prepared for 
TEM/CMP via osmication, b) embedded in epon blocs, and c) was serially sectioned at 90nm. Every 30 sections one was reserved 
for CMP analysis. D) TEM and CMP sections were imaged using a JEOL or Leica light microscope, respectively. Following 
image capture, sections were assembled, aligned, and imported into a Viking volume by custom software. E) Further annotation 
will continue in the Viking environment.
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Figure 6.3 Preliminary RPC1 data. A) 3D reconstruction of rod bipolar cell annotated in 
Viking, rendered in VikingView. B) Abnormal morphology ribbon synapses from the 
regions indicated in A. C) Hyperosmication of the protruding tip of a Müller cell invading 
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